{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MSEPO-21191 Cancer access policy 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 14,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document title:"
                    },
                    {
                        "text": "CANCER ACCESS POLICY"
                    },
                    {
                        "text": "Document reference/register no:"
                    },
                    {
                        "text": "MSEPO-21191"
                    },
                    {
                        "text": "Version number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Policy"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification issue date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "16 November 2021"
                    },
                    {
                        "text": "Review date:"
                    },
                    {
                        "text": "15 November 2024"
                    },
                    {
                        "text": "Key word(s) to search for document on intranet:"
                    },
                    {
                        "text": "Cancer, access, patients"
                    },
                    {
                        "text": "Developed in response to: (National guidance/recommendations (i.e. NICE; RCOG)"
                    },
                    {
                        "text": "Cancer Waiting Times Version 11 MSEFT Patient Access Policy (MSEPO-20229 v1.1) Going Further on Cancer Waits Achieving World Class Cancer Outcomes A strategy for England 2015 -2020 Inter Provider Transfer Policy \u2013 East of England Strategic Clinical Network V.3 Streamlining Multi-Disciplinary Team Meetings \u2013 Guidance for Cancer Alliances \u2013 Jan 2020"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Care group/division:"
                    },
                    {
                        "text": "Care Group 3"
                    },
                    {
                        "text": "Division 8"
                    },
                    {
                        "text": "Author/contact: (asset administrator)"
                    },
                    {
                        "text": "Nicola Baines"
                    },
                    {
                        "text": "Principal Physiologist/General Manager"
                    },
                    {
                        "text": "Hospital sites: (tick appropriate box(s) to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2612 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2610 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Approval group/ committee(s):"
                    },
                    {
                        "text": "Cancer Task and Finish Group (Clinical and Non-clinical representation)"
                    },
                    {
                        "text": "11 August 2021"
                    },
                    {
                        "text": "Professionally approved by: (Asset Owner)"
                    },
                    {
                        "text": "Clare Burns"
                    },
                    {
                        "text": "Director of Operations \u2013 Cancer"
                    },
                    {
                        "text": "08 October 2021"
                    },
                    {
                        "text": "Ratification group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "16 November 2021"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MSEPO-21191 Cancer access policy 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Executive and clinical directors (Communication of minutes from Joint Document Management Group)"
                    },
                    {
                        "text": "November 2021"
                    },
                    {
                        "text": "Distribution method:"
                    },
                    {
                        "text": "\u2612Trust Intranet"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted with: (Must include specialist pharmacists if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Maureen Ross"
                    },
                    {
                        "text": "General Manager \u2013 Cancer Access"
                    },
                    {
                        "text": "11 August 2021"
                    },
                    {
                        "text": "Jessica St-Pier Groves"
                    },
                    {
                        "text": "Project Manager"
                    },
                    {
                        "text": "11 August 2021"
                    },
                    {
                        "text": "Kia-Maria Luke"
                    },
                    {
                        "text": "Service Delivery Manager"
                    },
                    {
                        "text": "11 August 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Post/ Approval Committee/ Group: (Must include Medication Assurance Group if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "MSEFT Cancer Pathway Task and Finish Meeting"
                    },
                    {
                        "text": "11 August 2021"
                    },
                    {
                        "text": "Cancer Governance Board"
                    },
                    {
                        "text": "08 October 2021"
                    },
                    {
                        "text": "Cancer Committee"
                    },
                    {
                        "text": "04 November 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 7,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust documents (to be read in conjunction with)"
                    },
                    {
                        "text": "MSEPO-20229 Patient access policy MSEPO-21192 Cancer escalation policy"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 8,
            "data": {
                "num_rows": 5,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document review history:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ record documents superseded by:"
                    },
                    {
                        "text": "Issue date:"
                    },
                    {
                        "text": "0.02"
                    },
                    {
                        "text": "Nicola Baines"
                    },
                    {
                        "text": "16 November 2021"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "access policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Contents"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Introduction ................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "Scope ........................................................................................................................... 5"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Definitions ..................................................................................................................... 5"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Roles and responsibilities ............................................................................................. 7"
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Cancer patient access principles, guidelines and processes ...................................... 14"
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Monitoring and audit ................................................................................................... 52"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Approval and implementation ..................................................................................... 53"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Preliminary equality analysis ...................................................................................... 53"
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "References ................................................................................................................. 53 Appendix 1: Preliminary equality analysis .......................................................................... 55"
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Mid and South Essex NHS Foundation Trust (\u2018 the Trust') is committed to ensuring that patients receive treatment in accordance with the NHS Constitution, national objectives and targets, including \u2018'achieving World Class Cancer Outcomes and the Long Term Plan."
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "This policy sets out the Trust's local policy and operational standards associated with meeting the National Cancer Waiting Times and takes into account guidance from NHS England. This policy is designed to ensure efficient and equitable handling of referrals in line with national waiting time guidance relating to cancer pathways."
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "Patients' best interests are at the forefront of this policy. The timescales within which patients on a cancer pathway are treated is a vital quality issue and key indicator of the quality of cancer services offered at the Trust. In doing so, the Trust must meet the national Cancer Strategy standards and Cancer Waiting Times Guide version 11."
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "The purpose of this policy is to provide guidance and outline the rules for the management of patients on a cancer pathway and to act as an operational guide for those staff involved in the management of these pathways. It sets out the roles and responsibilities, processes to be followed and establishes a number of good practice guidelines to assist staff with the effective management of patients with suspected or diagnosed with cancer."
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.5,
                "text": "For patients, this policy will ensure that:"
            },
            "type": "ListItem",
            "sequence_num": 24
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients with suspected cancer and/or with a confirmed cancer diagnosis receive treatment in accordance with the National Cancer Waiting Times relevant to their cancer pathway, taking into account that they may choose to wait longer or clinically be unable to be seen or treated within these time frames."
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "data": {
                "is_heading": 1,
                "text": "All patients are treated according to clinical priority and those with the same clinical priority are treated in chronological order."
            },
            "type": "ListItem",
            "sequence_num": 26
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.6,
                "text": "For clinical and non-clinical staff, this policy will ensure that:"
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Teams and individuals are aware of their responsibilities for moving patients along the agreed clinical pathway in accordance with Cancer Waiting Times Guidance version 11."
            },
            "type": "ListItem",
            "sequence_num": 28
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Clinical support departments adhere to and monitor performance against agreed maximum waiting times for tests/investigations in their department."
            },
            "type": "ListItem",
            "sequence_num": 29
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Everyone involved in the Cancer pathway has a clear understanding of their roles and responsibilities, including the importance of timely communication both internally and externally, if transferred to other providers."
            },
            "type": "ListItem",
            "sequence_num": 30
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Accurate and complete data on the Trust's performance against the National Cancer Waiting Times is recorded in the Trust's Cancer Information System [currently Somerset Cancer Register Database (SCR)] and reported to the National Cancer Waiting Times Database (NHS Digital) within predetermined timescales."
            },
            "type": "ListItem",
            "sequence_num": 31
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            },
            "type": "ListItem",
            "sequence_num": 32
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "This policy applies to all Trust Staff involved in the care and management of cancer patients and to all patients with confirmed or suspected cancer cared for under Cancer Waiting Times Guidance as it applies to English NHS patients and as outlined in this policy."
            },
            "type": "ListItem",
            "sequence_num": 33
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "This policy does not cover patients who are seen, diagnosed and treated within 18 weeks from referral to treatment (RTT). Refer to the MSE Patient Access Policy (MSEPO-20229)."
            },
            "type": "ListItem",
            "sequence_num": 34
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            },
            "type": "ListItem",
            "sequence_num": 35
        },
        {
            "type": "table",
            "sequence_num": 36,
            "data": {
                "num_rows": 11,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "Active monitoring"
                    },
                    {
                        "text": "This is where a diagnosis has been reached but it is not appropriate to give active treatment at that point in time but an active treatment is still intended/may be required at a future date."
                    },
                    {
                        "text": "Active waiting list"
                    },
                    {
                        "text": "The list of patients who are fit and able to be at that point in time. The active waiting lists is also used to report national waiting time statistics"
                    },
                    {
                        "text": "Cancelled operations / procedures"
                    },
                    {
                        "text": "If the trust cancels a patient's operation or procedure on the day of, or after admission for non-clinical reasons \u2013 the Trust is required to rearrange treatment within 28 days of the cancelled date or within target wait time whichever is soonest."
                    },
                    {
                        "text": "CaRP (Cancer Referral Protocol form)"
                    },
                    {
                        "text": "A CaRP form is designed by the cancer network to be completed when a patient's care is transferred between NHS trusts. A form provides information on the current pathway status of a patient, including the referral and breach dates."
                    },
                    {
                        "text": "Chronological order (in turn)"
                    },
                    {
                        "text": "The general principle that applies to patients categorised as requiring routine treatment. All routine patients should be seen or treated in the order they were initially referred for treatment."
                    },
                    {
                        "text": "CWT"
                    },
                    {
                        "text": "Cancer Waiting Times (National Cancer Standards)"
                    },
                    {
                        "text": "Decision to admit (DTA)"
                    },
                    {
                        "text": "Where a clinical decision is made to admit the patient for either day case or inpatient treatment."
                    },
                    {
                        "text": "Decision to treat (DTT)"
                    },
                    {
                        "text": "Where a clinical decision is taken to treat a patient as an inpatient, day case or outpatient setting."
                    },
                    {
                        "text": "Did Not Attend (DNA)"
                    },
                    {
                        "text": "Patients who have agreed or been given reasonable notice of their appointment / treatment and who without notifying the Trust fail to attend."
                    },
                    {
                        "text": "ECAD"
                    },
                    {
                        "text": "Earliest clinically appropriate date (for next stage of treatment)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 37,
            "data": {
                "num_rows": 16,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "EPR"
                    },
                    {
                        "text": "Electronic Patient Record"
                    },
                    {
                        "text": "EROD"
                    },
                    {
                        "text": "Earliest Reasonable Offer Date"
                    },
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "First definitive treatment (FDT)"
                    },
                    {
                        "text": "An intervention intended to manage a patient's disease, condition or injury and avoid further intervention. What constitutes first definitive treatment is a matter of clinical judgment in consultation with other as appropriate, including the patient."
                    },
                    {
                        "text": "Multi-Disciplinary Team (MDT)"
                    },
                    {
                        "text": "An MDT comprises of medical and non-medical professionals who are responsible for the cancer patient's care. It includes clinicians from a variety of disciplines, the exact constituent are described for each tumour site as part of QSP requirements"
                    },
                    {
                        "text": "MDTC"
                    },
                    {
                        "text": "Multi-Disciplinary Team Coordinator"
                    },
                    {
                        "text": "MSEFT"
                    },
                    {
                        "text": "The three Trusts of Mid Essex; Southend and Basildon (\u2018the Trust' / \u2018MSEFT')"
                    },
                    {
                        "text": "NCG"
                    },
                    {
                        "text": "Network Clinical Group"
                    },
                    {
                        "text": "Outpatients"
                    },
                    {
                        "text": "Patients referred by a general practitioner (medical or dental) or another consultant / health professional for clinical advice or treatment."
                    },
                    {
                        "text": "PTL"
                    },
                    {
                        "text": "Patient Targeted List, a report use.d to ensure the maximum waiting time targets are achieved by identifying the patient wait time along their pathways and patients who are at risk of being outside the pathway requirements."
                    },
                    {
                        "text": "QSP"
                    },
                    {
                        "text": "Quality Surveillance Programme"
                    },
                    {
                        "text": "RTT"
                    },
                    {
                        "text": "Referral to treatment (18 week standard)"
                    },
                    {
                        "text": "SACT"
                    },
                    {
                        "text": "Systemic Anti-Cancer Therapy"
                    },
                    {
                        "text": "Somerset Cancer Register (SCR)"
                    },
                    {
                        "text": "A system in which all cancer patients are tracked and monitored. SCR is also used to support our reporting processes. Referred to as the Approved Cancer Information System."
                    },
                    {
                        "text": "SCN"
                    },
                    {
                        "text": "Strategic Clinical Network"
                    },
                    {
                        "text": "TCI (to come in)"
                    },
                    {
                        "text": "A proposed future date for an elective admission"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and responsibilities"
            },
            "type": "ListItem",
            "sequence_num": 38
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Chief Executive"
            },
            "type": "ListItem",
            "sequence_num": 39
        },
        {
            "data": {
                "is_heading": 0,
                "text": "As the the Trust's Accountable Officer, has overall responsibility for ensuring the MSEFT has robust, complete and up-to-date policies and procedures in place to govern and guide activities so that legal and national requirements are met."
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "Directors and Associate Directors"
            },
            "type": "ListItem",
            "sequence_num": 41
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Directors/Associate Directors, Divisional Directors and General Managers for each Division /Directorate have overall responsibility for implementing and adherence to this policy."
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This includes:"
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that effective processes are in place to manage patient care and treatment that meet national, local and NHS Constitution targets and standards for each specialty within the clinical division."
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing resources allocated to the clinical division with the aim of achieving access targets. This includes having the staff and other resources available to operate scheduled outpatient clinics, patient treatment and operating theatre sessions and avoid the need to cancel patient treatment."
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring capacity and demand modelling tools are updated at least yearly or as services change to ensure sufficient capacity is available to meet the needs of the patients being referred."
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Working with other Directors/Associate Directors, Divisional Directors and General Managers of service to provide a joined-up approach to implementing this policy and achieving the cancer access targets, particularly around outpatient and operating theatre capacity and availability of diagnostic services."
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Achieving cancer access targets."
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that the duties, responsibilities and processes laid down in this policy are implemented within the clinical division."
            },
            "type": "ListItem",
            "sequence_num": 49
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring all division staff that needs to operate this policy are aware of this policy and receive training so that they can meet the policy requirements."
            },
            "type": "ListItem",
            "sequence_num": 50
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Implement effective monitoring systems within the Divison to ensure compliance with this policy and avoid breaches of the targets: escalate any actual or potential breaches to the Chief Operating Officer."
            },
            "type": "ListItem",
            "sequence_num": 51
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Implementing systems and processes that support data quality and for validating data to ensure that all reports are accurate and produced within agreed timescales."
            },
            "type": "ListItem",
            "sequence_num": 52
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Day to day operational management of this policy will be delegated to Divisional/ Directorate Service/Operational managers and Clinical Leads as set out in the governance arrangements for each Directorate/ Clinical divisional group."
            },
            "type": "ListItem",
            "sequence_num": 53
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "Consultants"
            },
            "type": "ListItem",
            "sequence_num": 54
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Each consultant is responsible for:"
            },
            "type": "ListItem",
            "sequence_num": 55
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing the patients' care and treatment and working with their Directors/Associate Directors of Operations and Clinical lead, Divisional/ General Managers and clinical colleagues to ensure that this is provided within timescales laid down in national, local and NHS constitution targets and standards."
            },
            "type": "ListItem",
            "sequence_num": 56
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Alerting the Associate Director of Operations of any potential or actual breaches of targets."
            },
            "type": "ListItem",
            "sequence_num": 57
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that any patients with learning disabilities and autism have their special needs met in accordance with MSEFT Policy."
            },
            "type": "ListItem",
            "sequence_num": 58
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing staff within the medical team to ensure that scheduled outpatient clinics; patient treatment and operating theatre sessions are held and avoid the need to cancel patients."
            },
            "type": "ListItem",
            "sequence_num": 59
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing waiting lists and deciding on patient admissions / treatments in line with clinical priority."
            },
            "type": "ListItem",
            "sequence_num": 60
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Working with colleagues to prevent the cancellation of patient admissions for non-clinical reasons and taking action to reschedule any patients cancelled in line with timescales set out in this policy."
            },
            "type": "ListItem",
            "sequence_num": 61
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Communicating accurate waiting time information to patients, their families and carers and dealing with any queries, problems or complaints in line with trust policy."
            },
            "type": "ListItem",
            "sequence_num": 62
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Assisting with the monitoring of data quality and production of reports."
            },
            "type": "ListItem",
            "sequence_num": 63
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Supporting effective capacity and demand planning with specialist knowledge and pathway detail."
            },
            "type": "ListItem",
            "sequence_num": 64
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing the responsibilities of the MDT including attendance and annual leave cover."
            },
            "type": "ListItem",
            "sequence_num": 65
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "Referral Centre and those staff designated to make appointments including for outpatients, diagnostic tests and treatment are:"
            },
            "type": "ListItem",
            "sequence_num": 66
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "To receive fast track referrals, ensure that they are date stamped, and enter details on to the Trust's EPR within  hours."
            },
            "type": "ListItem",
            "sequence_num": 67
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To forward the referral when required to the appropriate consultant to assign clinical priority."
            },
            "type": "ListItem",
            "sequence_num": 68
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To make outpatient appointments that ensure the cancer standards are met."
            },
            "type": "ListItem",
            "sequence_num": 69
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To ensure all outpatient appointment offers are recorded on EPR."
            },
            "type": "ListItem",
            "sequence_num": 70
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To ensure cancellation reasons are recorded clearly on EPR."
            },
            "type": "ListItem",
            "sequence_num": 71
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To ensure EPR is updated correctly and in a timely fashion e.g. as soon as practicable with any patient choice decision."
            },
            "type": "ListItem",
            "sequence_num": 72
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To ensure the Cancer Information System (currently SCR) is updated and reflects a true and accurate record as depicted on PAS."
            },
            "type": "ListItem",
            "sequence_num": 73
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To refer any problems or suspected / potential breaches of policy or compliance with cancer targets to the appropriate Service or Operational Manager and copy to Associate Director of Operations for Cancer."
            },
            "type": "ListItem",
            "sequence_num": 74
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.5,
                "text": "Corporate Cancer Management Function"
            },
            "type": "ListItem",
            "sequence_num": 75
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.6,
                "text": "MDT coordinators"
            },
            "type": "ListItem",
            "sequence_num": 76
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Prepare, coordinate attend and tie up MDT meetings fully ensuring all listed patients are discussed in a timely manner."
            },
            "type": "ListItem",
            "sequence_num": 77
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure data entry is complete and accurate, meeting all CWT and COSD guidelines (i.e. FDS, ICD Diagnosis codes, histology and radiology reporting)."
            },
            "type": "ListItem",
            "sequence_num": 78
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Lead escalations at tumour site level as well as histology/ radiology."
            },
            "type": "ListItem",
            "sequence_num": 79
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Highlight any concerns or delays to Cancer Management."
            },
            "type": "ListItem",
            "sequence_num": 80
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Run and action COSD reporting for tumour sites to ensure performance remains high."
            },
            "type": "ListItem",
            "sequence_num": 81
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend cancer PTL meetings and provide updates as appropriate."
            },
            "type": "ListItem",
            "sequence_num": 82
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Track patients thoroughly, accurately and consistently onto the cancer information system at least twice weekly."
            },
            "type": "ListItem",
            "sequence_num": 83
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalate cancer patient pathway next steps as per the MSE cancer escalation policy."
            },
            "type": "ListItem",
            "sequence_num": 84
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.7,
                "text": "Cancer Patient Pathway Tracker / MDT Assistant"
            },
            "type": "ListItem",
            "sequence_num": 85
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure patients are tracked thoroughly and accurately on the cancer information system twice per week as per \u201csmart tracking\u201d."
            },
            "type": "ListItem",
            "sequence_num": 86
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure data entry is complete and accurate, meeting all CWT and COSD guidelines (i.e. FDS, ICD Diagnosis codes, histology and radiology reporting)."
            },
            "type": "ListItem",
            "sequence_num": 87
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Monitor daily escalation lists (at tumour site level as well as histology/ radiology) and highlight concerns to management."
            },
            "type": "ListItem",
            "sequence_num": 88
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend PTL meetings where appropriate stepping in for the MDT coordinator."
            },
            "type": "ListItem",
            "sequence_num": 89
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Assist with MDT preparation if required."
            },
            "type": "ListItem",
            "sequence_num": 90
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalate cancer pathway next steps as per the MSE cancer escalation policy."
            },
            "type": "ListItem",
            "sequence_num": 91
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.8,
                "text": "Cancer Navigator"
            },
            "type": "ListItem",
            "sequence_num": 92
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Track patients from a service level \u2013 managing STT pathways, chasing consultants and histology/radiology/genetic testing to reduce unnecessary interactions between clinical teams and Cancer Team"
            },
            "type": "ListItem",
            "sequence_num": 93
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Contacting patients to chase tests and arrange appointments etc."
            },
            "type": "ListItem",
            "sequence_num": 94
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Input limited data into the cancer information system, i.e. first seen dates, investigation dates and TCI dates."
            },
            "type": "ListItem",
            "sequence_num": 95
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend Cancer PTL meetings where appropriate."
            },
            "type": "ListItem",
            "sequence_num": 96
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend MDT meetings where appropriate."
            },
            "type": "ListItem",
            "sequence_num": 97
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend divisional meetings presenting cancer PTL data as appropriate."
            },
            "type": "ListItem",
            "sequence_num": 98
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalate cancer patient pathway next steps as per the MSE cancer escalation policy."
            },
            "type": "ListItem",
            "sequence_num": 99
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Track the completion of Harm Reviews through the department to panel."
            },
            "type": "ListItem",
            "sequence_num": 100
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.9,
                "text": "Multi-Disciplinary Team (MDT)"
            },
            "type": "ListItem",
            "sequence_num": 101
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An MDT comprises of medical and non-medical professionals who are responsible for the cancer patient's care. It includes clinicians from a variety of disciplines; the exact constituents are described for each tumour site as part of QSP requirements. It supports delivery of cancer standards by:"
            },
            "type": "ListItem",
            "sequence_num": 102
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Bringing together designated cancer specialists to discuss patient care and agreeing a treatment plan for individual patients"
            },
            "type": "ListItem",
            "sequence_num": 103
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Making sure care is planned according to national guidelines and to support clinical governance."
            },
            "type": "ListItem",
            "sequence_num": 104
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Identifying and supporting entry of patients into clinical trials."
            },
            "type": "ListItem",
            "sequence_num": 105
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that any patients with learning disabilities and autism have their special needs met in accordance with Trust Policy."
            },
            "type": "ListItem",
            "sequence_num": 106
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Monitoring and ensuring that there is good attendance by core members of the MDT so that decision making relevant to good practice and achievement of the cancer pathway."
            },
            "type": "ListItem",
            "sequence_num": 107
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Supporting the collection of good quality data relevant to clinical care and service improvement."
            },
            "type": "ListItem",
            "sequence_num": 108
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Reviewing its performance in terms of achieving safe and timely care in line with good practice and Cancer pathways standards."
            },
            "type": "ListItem",
            "sequence_num": 109
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Taking responsibility for changing pathways as required and those identified as a result of audit, data collection and performance information."
            },
            "type": "ListItem",
            "sequence_num": 110
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "MDT Clinical Lead"
            },
            "type": "ListItem",
            "sequence_num": 111
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Each tumour site will be led by a clinician who has site specific specialist knowledge of treating cancer. The clinical lead will:"
            },
            "type": "ListItem",
            "sequence_num": 112
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that objectives of MDT working are met (as laid out in National Manual of Cancer Service Standards)."
            },
            "type": "ListItem",
            "sequence_num": 113
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that designated specialists work effectively together in teams such that decisions regarding all aspects of diagnosis, treatment and care of individual patients and decisions regarding the team's operational policies are multidisciplinary decisions."
            },
            "type": "ListItem",
            "sequence_num": 114
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure mechanisms are in place to support entry of eligible patients into clinical trials, subject to patients giving fully informed consent."
            },
            "type": "ListItem",
            "sequence_num": 115
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that any patients with learning disabilities and autism have their special needs met in accordance with Trust Policy."
            },
            "type": "ListItem",
            "sequence_num": 116
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that the target of 100% of cancer patients discussed at the MDT is met adopting best practice of streamlining with standards of care as (per the Streamlining Multidisciplinary Team Meetings: Guidance for Cancer Alliance)."
            },
            "type": "ListItem",
            "sequence_num": 117
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that patient care pathways are in accordance with National Performance Standards."
            },
            "type": "ListItem",
            "sequence_num": 118
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that integration with Specialist MDTs (sMDTs) that are relevant to individual patient care is seamless."
            },
            "type": "ListItem",
            "sequence_num": 119
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that care is given according to recognised guidelines (including guidelines for onward referrals) with appropriate information being collected to inform clinical decision making and to support clinical governance/audit."
            },
            "type": "ListItem",
            "sequence_num": 120
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that treatment decisions made in the meeting are acted on and referrals made in a timely manner."
            },
            "type": "ListItem",
            "sequence_num": 121
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Overall responsibility for ensuring that MDT meeting and team meet Quality Surveillance Programme Measures."
            },
            "type": "ListItem",
            "sequence_num": 122
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure attendance levels of core members are maintained, in line with Quality Surveillance Programme Measures."
            },
            "type": "ListItem",
            "sequence_num": 123
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Provide link to Trust CSMB, either by attendance at meetings or by nominating another MDT member to attend."
            },
            "type": "ListItem",
            "sequence_num": 124
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Provide link to NCG (SCN), either by attendance at meetings or by nominating another MDT member to attend."
            },
            "type": "ListItem",
            "sequence_num": 125
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Lead on, or nominate lead for service improvement."
            },
            "type": "ListItem",
            "sequence_num": 126
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Organise and chair annual meeting examining functioning of team and reviewing operational policies, and collate any activities that are required to ensure optimal functioning of the team (e.g. training for team members)."
            },
            "type": "ListItem",
            "sequence_num": 127
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure MDT's activities are audited and results documented."
            },
            "type": "ListItem",
            "sequence_num": 128
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that root cause analyses are undertaken of cancer waiting time breaches in order to inform service development."
            },
            "type": "ListItem",
            "sequence_num": 129
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that the outcomes of the meeting are clearly recorded and clinically validated and that appropriate data collection is supported."
            },
            "type": "ListItem",
            "sequence_num": 130
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure target of communicating MDT outcomes to primary care is met."
            },
            "type": "ListItem",
            "sequence_num": 131
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.11,
                "text": "Clinical Tumour Pathway Lead"
            },
            "type": "ListItem",
            "sequence_num": 132
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The Clinical Tumour Pathway Lead has overall responsibility, delegated from the Chief Medical Officer (CMO), for the quality and patient experience of the cancer pathway;"
            },
            "type": "ListItem",
            "sequence_num": 133
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Take responsibility for an annual work programme for a cancer pathway (tumour specific) on behalf of MSEFT, providing updates to the MSE Cancer Board and presenting an annual report at the end of each year."
            },
            "type": "ListItem",
            "sequence_num": 134
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that decision making is multi-professional in nature and has a strong patient focus."
            },
            "type": "ListItem",
            "sequence_num": 135
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Help identify workforce, equipment and other needs within the pathway to achieve quality and access standards. Support investment decisions and comment on related business cases."
            },
            "type": "ListItem",
            "sequence_num": 136
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Lead discussions with other Clinical Tumour Pathway Leads and corresponding leads in other networks / integrated care systems on issues of common interest."
            },
            "type": "ListItem",
            "sequence_num": 137
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend the MSE Cancer Board to represent the cancer pathway."
            },
            "type": "ListItem",
            "sequence_num": 138
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Gain a robust understanding of the key opportunities to improve outcomes and experience by gathering and reviewing intelligence about the pathway."
            },
            "type": "ListItem",
            "sequence_num": 139
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Assist in developing operational policy for the group, and its associated multi-disciplinary clinical meetings (MDMs), as well as clinical guidelines that reflect best practice."
            },
            "type": "ListItem",
            "sequence_num": 140
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 62.0,
                "text": "Engage with the Harm Review process for patients treated outside the  day target."
            },
            "type": "ListItem",
            "sequence_num": 141
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Report risks to the MSEFT Clinical Chair for Cancer or MSEFT Cancer Board according to risk assessment framework."
            },
            "type": "ListItem",
            "sequence_num": 142
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that at least one audit is undertaken each year and that current research is reviewed and incorporated into practice."
            },
            "type": "ListItem",
            "sequence_num": 143
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Review recruitment into clinical trials and measures put in place to optimise participation."
            },
            "type": "ListItem",
            "sequence_num": 144
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Support full and active patient participation in the work of the Pathway Board and demonstrate how patient input has been used for the benefit of local people."
            },
            "type": "ListItem",
            "sequence_num": 145
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Work with the MSE Cancer Team to coordinate preparation for the annual QSP review, including self-assessment, internal validation and external visits (where applicable)."
            },
            "type": "ListItem",
            "sequence_num": 146
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.12,
                "text": "Cancer Nurse Specialists"
            },
            "type": "ListItem",
            "sequence_num": 147
        },
        {
            "data": {
                "is_heading": 0,
                "text": "It is appreciated that the role of the CNS will vary between areas and sites and needs to be flexible to meet the requirements of the service. However there are core elements which are nationally recognised requirements and it is recommended by the Strategic Clinical Network that these core elements are included within all cancer CNS Job plans:"
            },
            "type": "ListItem",
            "sequence_num": 148
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Providing holistic needs assessment for every cancer patient post diagnosis and post treatment."
            },
            "type": "ListItem",
            "sequence_num": 149
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Developing care plans and supporting development of treatment summaries."
            },
            "type": "ListItem",
            "sequence_num": 150
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Direct patient contact / clinical activity \u2013 including Nurse Led Clinics, STT triage, MDT, Multidisciplinary clinics, supporting and development of health and wellbeing events, telephone follow-up."
            },
            "type": "ListItem",
            "sequence_num": 151
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Supporting seamless patient pathways."
            },
            "type": "ListItem",
            "sequence_num": 152
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attendance / support of PTL /cancer services teams."
            },
            "type": "ListItem",
            "sequence_num": 153
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Supporting improving access to clinical trials."
            },
            "type": "ListItem",
            "sequence_num": 154
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Administration supporting direct patient care/MDT prep/follow up as appropriate."
            },
            "type": "ListItem",
            "sequence_num": 155
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure compliance with the guidance in this operational policy."
            },
            "type": "ListItem",
            "sequence_num": 156
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.13,
                "text": "Cancer Service Delivery Manager"
            },
            "type": "ListItem",
            "sequence_num": 157
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Provides overall reporting of Trust performance against Cancer standards."
            },
            "type": "ListItem",
            "sequence_num": 158
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensures there are sufficient governance and performance management arrangements in place to robustly support the delivery of cancer performance."
            },
            "type": "ListItem",
            "sequence_num": 159
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Lead on improvements to Cancer access standards."
            },
            "type": "ListItem",
            "sequence_num": 160
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Be the trust management representative on the cancer network group meetings."
            },
            "type": "ListItem",
            "sequence_num": 161
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring the policy is kept up to date and reflects national best practice guidance."
            },
            "type": "ListItem",
            "sequence_num": 162
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Providing expert advice on cancer pathways across the organisation, including advice from national team if required."
            },
            "type": "ListItem",
            "sequence_num": 163
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring trust wide compliance with the policy and carrying out spot check audits to check compliance."
            },
            "type": "ListItem",
            "sequence_num": 164
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Work with the individual services in their delivery of the cancer standards."
            },
            "type": "ListItem",
            "sequence_num": 165
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Provide leadership and support to the Cancer Waiting List/MDT Managers so that they provide a high quality service to the site specific MDTs."
            },
            "type": "ListItem",
            "sequence_num": 166
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.14,
                "text": "General Medical / Dental Practitioners and other referrers"
            },
            "type": "ListItem",
            "sequence_num": 167
        },
        {
            "data": {
                "is_heading": 0,
                "text": "MSEFT relies on GPs/GDPs and other referrers, supported by local commissioners to ensure patients understand their responsibilities and potential pathway steps and timescales when being referred. This will help ensure patients are:"
            },
            "type": "ListItem",
            "sequence_num": 168
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Referred under appropriate clinical guidelines."
            },
            "type": "ListItem",
            "sequence_num": 169
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure they use agreed referral proformas / protocols, provide the required clinical information and patient demographics."
            },
            "type": "ListItem",
            "sequence_num": 170
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Offered a choice of provider as outlined in national guidance."
            },
            "type": "ListItem",
            "sequence_num": 171
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Aware of the speed at which their pathway may be progressed."
            },
            "type": "ListItem",
            "sequence_num": 172
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In the best possible position to accept timely appointments throughout their treatment."
            },
            "type": "ListItem",
            "sequence_num": 173
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.15,
                "text": "Patients"
            },
            "type": "ListItem",
            "sequence_num": 174
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Everyone has a role to play to ensure that the Trust is able to deliver care within the Cancer pathways."
            },
            "type": "ListItem",
            "sequence_num": 175
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients also have a role to play as outlined in the NHS Constitution these include:"
            },
            "type": "ListItem",
            "sequence_num": 176
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Make themselves available for the two months after referral for reasonable appointments."
            },
            "type": "ListItem",
            "sequence_num": 177
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attending their hospital appointment or ensuring that they contact the hospital to cancel it, giving as much notice as possible if they are unable to attend."
            },
            "type": "ListItem",
            "sequence_num": 178
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Managing their own health where possible."
            },
            "type": "ListItem",
            "sequence_num": 179
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Using the part of the service appropriate for their needs."
            },
            "type": "ListItem",
            "sequence_num": 180
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Being involved in the management of their treatment pathway."
            },
            "type": "ListItem",
            "sequence_num": 181
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that they inform their healthcare provider of any changes in personal circumstances, particularly contact details and registered GP."
            },
            "type": "ListItem",
            "sequence_num": 182
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.16,
                "text": "All staff"
            },
            "type": "ListItem",
            "sequence_num": 183
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All staff are responsible for ensuring that any data created, edited, used or recorded on the Trust's information systems within their area of responsibility is accurate recorded in accordance with this policy and other trust polices relating to the collection, storage and use of data in order to maintain the highest standards of data quality and maintain patient confidentiality."
            },
            "type": "ListItem",
            "sequence_num": 184
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All patient referrals, treatment episodes and waiting lists must be managed on the Trust's Cancer Information System and all information relating to patient activity must be recorded accurately and in a timely fashion and where appropriate all requests stamped with the 2ww stamp."
            },
            "type": "ListItem",
            "sequence_num": 185
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Cancer patient access principles, guidelines and processes"
            },
            "type": "ListItem",
            "sequence_num": 186
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Key principles"
            },
            "type": "ListItem",
            "sequence_num": 187
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "This policy will be applied consistently and without exception across the Trust. This will ensure that all patients are treated equitably and according to their clinical need and is inclusive of military patients. Patients on cancer pathways will be prioritised according to national guidance. Non-NHS patients including overseas visitors are not covered by this policy and should be managed according to clinical priority and the overseas visitor policy."
            },
            "type": "ListItem",
            "sequence_num": 188
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "Patients will be treated in order of their clinical need. Patients of the same or comparable clinical priority will be treated on a \u2018first come first served' principle, according to case mix."
            },
            "type": "ListItem",
            "sequence_num": 189
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "The process of waiting list management for patients suspected of or diagnosed with cancer will be transparent to the public and communications with patients (or parents/carers and vulnerable patients) will be timely and informative clear and concise."
            },
            "type": "ListItem",
            "sequence_num": 190
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Waiting lists will be managed equitably with no preference shown on the basis of provider or source of referral."
            },
            "type": "ListItem",
            "sequence_num": 191
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Summary of cancer waiting times operational standards"
            },
            "type": "ListItem",
            "sequence_num": 192
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.7,
                "text": "The cancer waiting times (operational) standards are described in detail in National Cancer Waiting Times Monitoring Dataset Version 11. The standards are summarised below:"
            },
            "type": "ListItem",
            "sequence_num": 193
        },
        {
            "type": "table",
            "sequence_num": 194,
            "data": {
                "num_rows": 8,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Standard"
                    },
                    {
                        "text": "Operational Standard"
                    },
                    {
                        "text": "Maximum two weeks from:"
                    },
                    {
                        "text": "Receipt of urgent referral for suspected cancer to first outpatient attendance"
                    },
                    {
                        "text": "93%"
                    },
                    {
                        "text": "Receipt of referral of any patient with breast symptoms (where cancer not suspected) to first hospital assessment"
                    },
                    {
                        "text": "93%"
                    },
                    {
                        "text": "Maximum 28 days from:"
                    },
                    {
                        "text": "Receipt of two week wait referral for suspected cancer, receipt of urgent referral from a cancer screening programme (breast, bowel, cervical), and receipt of two week wait referral of any patient with breast symptoms (where cancer not suspected), to the date the patient is informed of a diagnosis or ruling out of cancer"
                    },
                    {
                        "text": "75%"
                    },
                    {
                        "text": "Maximum 31 days from:"
                    },
                    {
                        "text": "Decision to treat to first definitive treatment"
                    },
                    {
                        "text": "96%"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 195,
            "data": {
                "num_rows": 9,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Decision to treat/earliest clinically appropriate date to start of second or subsequent treatment(s) for all cancer patients including those diagnosed with a recurrence where the subsequent treatment is:"
                    },
                    {
                        "text": "Surgery"
                    },
                    {
                        "text": "94%"
                    },
                    {
                        "text": "SACT"
                    },
                    {
                        "text": "98%"
                    },
                    {
                        "text": "Radiotherapy"
                    },
                    {
                        "text": "94%"
                    },
                    {
                        "text": "Maximum 62 days from:"
                    },
                    {
                        "text": "Urgent referral for suspected cancer to first treatment (62-day classic)"
                    },
                    {
                        "text": "85%"
                    },
                    {
                        "text": "Urgent referral from a NHS Cancer Screening Programme (breast, cervical or bowel) for suspected cancer to first treatment"
                    },
                    {
                        "text": "90%"
                    },
                    {
                        "text": "No separate operational standards set"
                    },
                    {
                        "text": "Consultant upgrade of urgency of a referral to first treatment"
                    },
                    {
                        "text": "Maximum one month (31 days) from urgent referral to first treatment for rare cancers: acute leukaemia, testicular cancer and children's cancers (monitored within the 62 day standard)."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "Inclusion / Exclusion from Cancer Waiting times Standards"
            },
            "type": "ListItem",
            "sequence_num": 196
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.9,
                "text": "Patients included"
            },
            "type": "ListItem",
            "sequence_num": 197
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Cancer waiting time service standards are applicable to patients cared for under the NHS in England with ICD codes C00-C97 (excluding basal cell carcinoma) and D05 (all carcinoma in situ \u2013 breast) this includes those patients:"
            },
            "type": "ListItem",
            "sequence_num": 198
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Being treated within a clinical trial."
            },
            "type": "ListItem",
            "sequence_num": 199
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Whose cancer care is undertaken by a private provider on behalf of the NHS i.e. directly commissioned by an NHS commissioner."
            },
            "type": "ListItem",
            "sequence_num": 200
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Whose care is sub-contracted to another provider \u2013 including private provider \u2013 (and hence paid for) by an English NHS provider i.e. commissioned by an NHS commissioner but sub-contracted out by a commissioned provider."
            },
            "type": "ListItem",
            "sequence_num": 201
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Diagnosed with a second new cancer."
            },
            "type": "ListItem",
            "sequence_num": 202
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Without microscopic verification of the tumour (i.e. histology or cytology) if the patient has been told they have and /or have received treatment for cancer."
            },
            "type": "ListItem",
            "sequence_num": 203
        },
        {
            "data": {
                "is_heading": 0,
                "text": "With any skin squamous cell carcinoma (SCC) for example: Every SCC an individual skin cancer patient has will be covered by the standards."
            },
            "type": "ListItem",
            "sequence_num": 204
        },
        {
            "data": {
                "is_heading": 1,
                "text": "In terms of specific standards it should be noted that:"
            },
            "type": "ListItem",
            "sequence_num": 205
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS patients with a newly diagnosed invasive cancer (localised or metastatic)."
            },
            "type": "ListItem",
            "sequence_num": 206
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS patients with a recurrence of a previously diagnosed cancer."
            },
            "type": "ListItem",
            "sequence_num": 207
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS patients with a new diagnosis of cancer or a recurrence regardless of the route of referral \u2013 this will include patients who may be diagnosed with cancer during routine investigations or while being treated for another condition \u2013 incidental finding."
            },
            "type": "ListItem",
            "sequence_num": 208
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients who choose initially to be seen privately but are then referred for first / subsequent treatments with the NHS."
            },
            "type": "ListItem",
            "sequence_num": 209
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Through the two week wait referral route by their GP/GDP with suspected cancer."
            },
            "type": "ListItem",
            "sequence_num": 210
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Urgently from any of the 3 national cancer screening programmes (breast cervical bowel)."
            },
            "type": "ListItem",
            "sequence_num": 211
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Then upgraded by a consultant or authorised member of consultant team because cancer is suspected."
            },
            "type": "ListItem",
            "sequence_num": 212
        },
        {
            "data": {
                "is_heading": 0,
                "text": "On suspicion of one cancer but diagnosed."
            },
            "type": "ListItem",
            "sequence_num": 213
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Patients excluded:"
            },
            "type": "ListItem",
            "sequence_num": 214
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Cancer waiting times service standards are not applicable to patients:"
            },
            "type": "ListItem",
            "sequence_num": 215
        },
        {
            "data": {
                "is_heading": 0,
                "text": "With a non-invasive cancer i.e.:"
            },
            "type": "ListItem",
            "sequence_num": 216
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Who die prior to treatment commencing \u2013 local systems will need to be able to flag this and forward the information to cancer registries."
            },
            "type": "ListItem",
            "sequence_num": 217
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Receiving diagnostic services and treatment privately. However:"
            },
            "type": "ListItem",
            "sequence_num": 218
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Who refuse all reasonable offers of diagnostics or treatments, or opt to be treated outside of the NHS."
            },
            "type": "ListItem",
            "sequence_num": 219
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.11,
                "text": "Cancer pathways key dates"
            },
            "type": "ListItem",
            "sequence_num": 220
        },
        {
            "type": "image",
            "sequence_num": 221,
            "data": {
                "url": "MSEPO-21191 Cancer access policy 1.0.003.jpeg"
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.12,
                "text": "The 2 week wait standard and first seen standard specifics"
            },
            "type": "ListItem",
            "sequence_num": 222
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.13,
                "text": "2ww summary"
            },
            "type": "ListItem",
            "sequence_num": 223
        },
        {
            "type": "table",
            "sequence_num": 224,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Standard"
                    },
                    {
                        "text": "Applies to"
                    },
                    {
                        "text": "Start"
                    },
                    {
                        "text": "Stop"
                    },
                    {
                        "text": "Target"
                    },
                    {
                        "text": "Operational Standard"
                    },
                    {
                        "text": "2ww Suspected Cancer"
                    },
                    {
                        "text": "Patients who are referred in by their GP/ dentist/ optometrist/ other referral source as agreed as a suspected cancer must be given an appointment within two weeks (e.g. in a clinic or for a test if on a STT pathway)"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Date first seen"
                    },
                    {
                        "text": "14 days"
                    },
                    {
                        "text": "93%"
                    },
                    {
                        "text": "2ww Breast Symptomatic"
                    },
                    {
                        "text": "Patients who are referred by their GP who are not suspecting breast cancer but must be referred in as a 2ww have to be seen for the first time within two weeks"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Date first seen"
                    },
                    {
                        "text": "14 days"
                    },
                    {
                        "text": "93%"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.14,
                "text": "2ww Coverage"
            },
            "type": "ListItem",
            "sequence_num": 225
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.15,
                "text": "Referrals for suspected cancer"
            },
            "type": "ListItem",
            "sequence_num": 226
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The two week wait standard applies to patients referred with suspected cancer from one of the following referrers:"
            },
            "type": "ListItem",
            "sequence_num": 227
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Systems are in place to allow GPs, GDP and Optometrist to make urgent suspected cancer referrals, and symptomatic breast referrals to be made from any route. Referrals can be made and recorded via other sources for urgent referrals where this is locally agreed jointly by commissioners and"
            },
            "type": "ListItem",
            "sequence_num": 228
        },
        {
            "data": {
                "is_heading": 0,
                "text": "providers. Examples of where this could be expanded include referrals from other healthcare professionals such as an Advanced Nurse Practitioner (ANP) or referral direct from an AandE attendance into a suspected cancer referral clinic."
            },
            "type": "ListItem",
            "sequence_num": 229
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The standards apply to all NHS providers and private providers either where the activity is directly commissioned by an NHS England commissioner or sub- contracted by an NHS provider."
            },
            "type": "ListItem",
            "sequence_num": 230
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.16,
                "text": "Referrals for suspected recurrence of cancer"
            },
            "type": "ListItem",
            "sequence_num": 231
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A GP (or other referrer) can make an urgent two week wait referral for a suspected recurrence or a suspected second new primary cancer."
            },
            "type": "ListItem",
            "sequence_num": 232
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The two week wait first seen and Faster Diagnosis Standard would apply."
            },
            "type": "ListItem",
            "sequence_num": 233
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the urgent two week wait referral is diagnosed as a recurrence they are covered by the 31 day subsequent treatment standard."
            },
            "type": "ListItem",
            "sequence_num": 234
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the urgent 2ww referral is diagnosed as a new primary the patient moves onto the 62 day pathway."
            },
            "type": "ListItem",
            "sequence_num": 235
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.17,
                "text": "2ww Clock start and end dates"
            },
            "type": "ListItem",
            "sequence_num": 236
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.18,
                "text": "Clock start date (D = 0)"
            },
            "type": "ListItem",
            "sequence_num": 237
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 2ww start point is the receipt of the referral (day zero) by the provider who will first see the patient (recorded as the cancer referral to treatment period start date)."
            },
            "type": "ListItem",
            "sequence_num": 238
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Referrals received after a working day has finished should have the cancer referral to treatment period start date set as the date that the referral was received and not the next working day."
            },
            "type": "ListItem",
            "sequence_num": 239
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If further information is required to manage the referral the receipt of initial referral would still count as day zero."
            },
            "type": "ListItem",
            "sequence_num": 240
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.19,
                "text": "Clock end date"
            },
            "type": "ListItem",
            "sequence_num": 241
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The two week wait end point is either when:"
            },
            "type": "ListItem",
            "sequence_num": 242
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A telephone consultation or triage does not count as a clock stop for the two week wait standards."
            },
            "type": "ListItem",
            "sequence_num": 243
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Trust aims for patients on the 2ww pathway to be first seen by day 7 in order to meet the 2ww operational standard."
            },
            "type": "ListItem",
            "sequence_num": 244
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Patient seen as an emergency prior to being seen following a 2ww referral"
            },
            "type": "ListItem",
            "sequence_num": 245
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a 2ww patient is admitted as an emergency for the same condition (i.e. related to the suspected cancer) before they are seen they should no longer be recorded against the two week wait standard, or 28-day FDS. The emergency admission is the referral into the system and supersedes the original referral. However, the patient could be upgraded to the 62-day pathway if a consultant or authorised member of their team suspect's cancer is the cause of the admission."
            },
            "type": "ListItem",
            "sequence_num": 246
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This would not apply where a patient attends an accident and emergency (A and E) department and is not admitted. In such a scenario the original clock start would apply."
            },
            "type": "ListItem",
            "sequence_num": 247
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.21,
                "text": "Symptomatic breast referrals"
            },
            "type": "ListItem",
            "sequence_num": 248
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The difference between the urgent GP 2ww referral and the symptomatic breast 2ww referral depends on whether the referrer suspects cancer or not. Breast symptoms are defined as any breast symptoms (covered in the NICE NG12 guidelines: Suspected cancer: recognition and referral) that a healthcare professional believes need to be seen by a specialist, excluding referrals from family history clinics (unless a patient is symptomatic) or for cosmetic breast surgery."
            },
            "type": "ListItem",
            "sequence_num": 249
        },
        {
            "data": {
                "is_heading": 0,
                "text": "These referrals can be distinguished from suspected cancer 2ww referrals through the data item TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE where the breast symptomatic patients are given the code \u201816'."
            },
            "type": "ListItem",
            "sequence_num": 250
        },
        {
            "data": {
                "is_heading": 1,
                "text": "For a NHS cancer screening provider, this would only be patients exhibiting symptoms (not screening results) with a priority type of \u201803'."
            },
            "type": "ListItem",
            "sequence_num": 251
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.22,
                "text": "First seen adjustment"
            },
            "type": "ListItem",
            "sequence_num": 252
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An adjustment to the DATE FIRST SEEN is allowed if a patient does not attend (DNAs) the allocated appointment time and gives no notice for their initial out-patient or diagnostic Appointment."
            },
            "type": "ListItem",
            "sequence_num": 253
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the patient turns up in a condition where it is not possible to carry out the required procedure (e.g. if they have not taken a preparation they needed to take prior to the appointment), this should be recorded as DNA."
            },
            "type": "ListItem",
            "sequence_num": 254
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the patient arrives after the scheduled appointment time and it is not possible to fit them in (e.g. fully booked) or there is not enough time left to carry out the planned procedure/tests in the remainder of the session then this is classed as a DNA."
            },
            "type": "ListItem",
            "sequence_num": 255
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Under this adjustment, the clock can be reset from the receipt of the referral (recorded as the CANCER REFERRAL TO TREATMENT PERIOD START DATE) to the date upon which either the patient makes contact to re-book their appointment or the date the appointment is re-booked should the patient not directly contact the Trust to do so. This period is called the WAITING TIME ADJUSTMENT (FIRST SEEN) and is effectively deducted from the total waiting time."
            },
            "type": "ListItem",
            "sequence_num": 256
        },
        {
            "data": {
                "is_heading": 1,
                "text": "An adjustment is not possible if a patient cancels or reschedules an appointment, or is not available to be seen for a period of time."
            },
            "type": "ListItem",
            "sequence_num": 257
        },
        {
            "type": "table",
            "sequence_num": 258,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "If a patient DNAs their initial OPA how should the process of re-booking be managed?"
                    },
                    {
                        "text": "If a patient DNAs their initial OPA, the provider should proactively contact the patient (e.g. by phone) to start the process of re-booking. However, if a patient cancels their first out-patient appointment and then DNAs the rearranged date, the clock can be reset to the date the appointment is rebooked by using the WAITING TIME ADJUSTMENT (FIRST SEEN)."
                    },
                    {
                        "text": "Can an adjustment be made if a patient DNAs the first OPA after a consultant upgrade onto a 62- day standard?"
                    },
                    {
                        "text": "The adjustment for when patients DNA the first out-patient appointment can be used for the consultant upgrade route up to and including the DATE FIRST SEEN. As most referrals along this route occur at the same time as the DATE FIRST SEEN, this adjustment will be rare but should occur if a consultant upgrades a patient after reading a referral letter but then the patient DNAs."
                    },
                    {
                        "text": "Can adjustments be made if a patient DNAs a diagnostic appointment?"
                    },
                    {
                        "text": "An adjustment is only possible if a patient does not attend their first attendance. So, where the diagnostic appointment is also the first attendance an adjustment should be applied. A DNA for a diagnostic appointment cannot be used as an adjustment if it occurs after the first attendance."
                    },
                    {
                        "text": "What is the position on adjustments if a patient wishes to wait for a specific"
                    },
                    {
                        "text": "No adjustment would be possible in this scenario. Adjustments are only possible if a patient DNAs their first attendance or after a Decision to Treat has been made."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 259,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "diagnostic option?"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.23,
                "text": "Management of DNAs and cancellations"
            },
            "type": "ListItem",
            "sequence_num": 260
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Patients should not be referred back to their GP after a single Did Not Attend (DNA) or cancellation. Patients should only be referred back to their GP after multiple DNAs following a clinical decision to do so."
            },
            "type": "ListItem",
            "sequence_num": 261
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Patients should never be referred back to their GP after an appointment cancellation unless this has been agreed with the patient \u2013 by cancelling an appointment a patient has shown a willingness to engage with the NHS."
            },
            "type": "ListItem",
            "sequence_num": 262
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.24,
                "text": "Principles for managing 2ww referrals"
            },
            "type": "ListItem",
            "sequence_num": 263
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.25,
                "text": "Referral policy and guidance"
            },
            "type": "ListItem",
            "sequence_num": 264
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The following are national requirements for management of 2ww referrals:"
            },
            "type": "ListItem",
            "sequence_num": 265
        },
        {
            "data": {
                "is_heading": 1,
                "text": "If a consultant thinks the two week wait referral is inappropriate this should be discussed with the referrer. Only the referrer can downgrade or withdraw a referral. This includes where it is considered that insufficient information has been provided."
            },
            "type": "ListItem",
            "sequence_num": 266
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The date of receipt of initial referral or the conversion of the UBRN into a booking should always count as the start of the pathway and recorded as CANCER REFFERAL TO TREATMENT PERIOD START DATE. This includes scenarios where additional information is requested from the referrer and where a patient is unavailable for a period of time."
            },
            "type": "ListItem",
            "sequence_num": 267
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A patient should not be discharged because they are unavailable within a specified time-frame, and processes should be in place to ensure patients have the choice to book outside of the two week wait time-frame."
            },
            "type": "ListItem",
            "sequence_num": 268
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The following are good practice guidelines for the management of 2ww referrals, though these do not override the national requirements above:"
            },
            "type": "ListItem",
            "sequence_num": 269
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The best interest of the patient should always be at the forefront of decision making;"
            },
            "type": "ListItem",
            "sequence_num": 270
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Trust should run daily checks for missing referral letters following an e- Referral Service (e-RS) referral, and follow these up with the relevant GP practices"
            },
            "type": "ListItem",
            "sequence_num": 271
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The duty of care is with the referring practice. The practice will therefore need to have systems in place to ensure that referral letters are sent promptly and to ensure that patients they have referred convert their"
            },
            "type": "ListItem",
            "sequence_num": 272
        },
        {
            "data": {
                "is_heading": 0,
                "text": "UBRNs in a timely way, where patients book their appointments directly through the e-referrals system"
            },
            "type": "ListItem",
            "sequence_num": 273
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For 2ww referrals the required information should be sent to the Trust within one working day of the GP referral."
            },
            "type": "ListItem",
            "sequence_num": 274
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the required information is still missing after one working day, every effort should be made to contact the referrer to obtain this information. However the referral should not be withdrawn or downgraded on these grounds. Escalation to the named contact in CCG will be required in this case."
            },
            "type": "ListItem",
            "sequence_num": 275
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The patient should be encouraged to accept the earliest appointment. NICE Suspected cancer: recognition and referral NG12 guidelines explain the information that should be provided to the patient to encourage patients to accept the earliest appointment where possible. It would also be helpful for the referrer to reiterate the importance of keeping an appointment once it has been made. Communication should be tailored to the needs of local communities to best encourage attendance."
            },
            "type": "ListItem",
            "sequence_num": 276
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.26,
                "text": "NHS e-Referrals Service (e-RS)"
            },
            "type": "ListItem",
            "sequence_num": 277
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For patients booking an appointment through the e-RS it is good practice to ensure the patient has booked an appointment before leaving the practice. It is also good practice to ensure that someone at the practice monitors e- RS bookings on a daily basis to check that all UBRNs have been converted into a booking."
            },
            "type": "ListItem",
            "sequence_num": 278
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For urgent 2ww appointments, e-RS will only offer patients an appointment within the next 14 day period. If a patient cannot make themselves available for an appointment within two weeks, despite having been given appropriate information, it is technically possible for a GP or other referrer to defer making the referral until the patient is available for referral."
            },
            "type": "ListItem",
            "sequence_num": 279
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients who choose an appointment outside of two weeks do not exempt themselves from the standards. The operational standards for the 2ww commitments take account of the volume of patients likely to be seen outside of two weeks due to patient choice."
            },
            "type": "ListItem",
            "sequence_num": 280
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.27,
                "text": "Referrals not made via e-RS"
            },
            "type": "ListItem",
            "sequence_num": 281
        },
        {
            "data": {
                "is_heading": 0,
                "text": "MSEFT receives referrals via e-RS unless they are routed in from out-of-hours GPs. Referrals via fax or email are not generally accepted. However, for 2ww urgent referrals received by a route other than e-RS e.g. letter, fax or email, referrals should not be automatically rejected in the interests of patient safety. A patient should be offered an appointment if the GP practice is unable to book on e- RS within a two hour period. The nationally recommended process for this is included below. In the interest of patient safety, if there is no response from the GP practice within the next working day, the provider will contact the patient to make an appointment, regardless of whether they have received the e-RS referral from the GP practice or not."
            },
            "type": "ListItem",
            "sequence_num": 282
        },
        {
            "type": "image",
            "sequence_num": 283,
            "data": {
                "url": "MSEPO-21191 Cancer access policy 1.0.005.jpeg"
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.28,
                "text": "Receiving a referral in error"
            },
            "type": "ListItem",
            "sequence_num": 284
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Referrers should know where to send patients. If they have sent a referral in error to us as a Trust, we should liaise with the referrer and ask them to withdraw the referral and re-refer to a correct provider. This new referral would be recorded as the start of the 2ww. Alternatively, if we, as a Trust, have received a referral in error, we could forward this referral to the correct provider, if this is faster and in the patient's interest. In this case the two week wait clock start would still be the original from the referrer."
            },
            "type": "ListItem",
            "sequence_num": 285
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.29,
                "text": "Abnormal direct access diagnostic and screening programmes"
            },
            "type": "ListItem",
            "sequence_num": 286
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Triage from an abnormal direct access diagnostic"
            },
            "type": "ListItem",
            "sequence_num": 287
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a pathway has been implemented and agreed locally where a patient is directly triaged from an abnormal direct access diagnostic scan with a suspicion of cancer then the decision to triage directly would act as the start of the pathway."
            },
            "type": "ListItem",
            "sequence_num": 288
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The CANCER REFERRAL TO TREATMENT START DATE (clock start) should be recorded as the date of triage into secondary care management."
            },
            "type": "ListItem",
            "sequence_num": 289
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "The SOURCE OF REFERRAL FOR OUT PATIENTS should be recorded as  - referral from a GENERAL MEDICAL PRACTITIONER."
            },
            "type": "ListItem",
            "sequence_num": 290
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The DATE FIRST SEEN would then be recorded as the next appointment or diagnostic as outlined in 5.5.3.2."
            },
            "type": "ListItem",
            "sequence_num": 291
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If local arrangements mean the two week wait urgent referral is received prior to the direct access diagnostic, then the date the two week wait urgent referrals is received by the provider should be used as the CANCER REFERRAL TO TREATMENT START DATE."
            },
            "type": "ListItem",
            "sequence_num": 292
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This can apply to any pathway. Examples of its application are included below for lung and oesophago-gastric cancers as detailed in the rapid cancer diagnostic and assessment pathways on the NHS England website."
            },
            "type": "ListItem",
            "sequence_num": 293
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where this is applied the CANCER DIAGNOSTIC REFERRAL ROUTE should be recorded as 01 (Abnormal diagnostics results following a NICE guidance NG12 referral to a direct access diagnostic service)."
            },
            "type": "ListItem",
            "sequence_num": 294
        },
        {
            "type": "table",
            "sequence_num": 295,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Timed diagnostic pathway for lung cancer"
                    },
                    {
                        "text": "This pathway sets out how a patient could be transferred to secondary care without an additional referral from their GP, if the patient has had an abnormal result for a direct access chest x-ray followed by an abnormal CT result, and a site specific escalation process to secondary care is followed. Where a patient is transferred to MSEFT this should be recorded as an Urgent Suspected Cancer referral, following triage of the CT resulting in follow-up being required in secondary care. The CANCER REFERRAL TO TREATMENT START DATE (clock start) should be recorded as the date of this triage."
                    },
                    {
                        "text": "Timed diagnostic pathway for oesophago- gastric cancer"
                    },
                    {
                        "text": "This pathway outlines a diagnosis pathway for patients referred with oesophageal or gastric cancer symptoms. It is acknowledged that this pathway could start with an urgent direct access upper gastrointestinal endoscopy ordered by the GP (satisfying relevant NG12 risk criteria). Where the upper gastrointestinal endoscopy is abnormal and suspicious of cancer, patients could be followed up by MSEFT directly from endoscopy without the need for an additional referral from GP. In this case, the decision to escalate the patient (i.e. decision to follow up the patient at MSEFT) should be counted as an Urgent Suspected Cancer referral. The CANCER REFERRAL TREATMENT START DATE (clock start) should be recorded as the date of this decision , which would usually be the date of the endoscopy itself where an abnormality is seen."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.31,
                "text": "Screening programmes"
            },
            "type": "ListItem",
            "sequence_num": 296
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The 2ww standard does not apply to patients from the NHS national cancer screening programmes. However, it is important that clock start, the first seen activity and clock end is recorded for monitoring of the 28-day FDS and 62-day screening standard if cancer is confirmed."
            },
            "type": "ListItem",
            "sequence_num": 297
        },
        {
            "data": {
                "is_heading": 1,
                "text": "When does the 28day FDS and 62-day standard START for the three NHS cancer screening programmes?"
            },
            "type": "ListItem",
            "sequence_num": 298
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The clock start (day 0) is when a referral is received by the MSEFT hospital site in the screening pathway for further investigation after an initial screening test. Each individual screening programme is as follows:"
            },
            "type": "ListItem",
            "sequence_num": 299
        },
        {
            "data": {
                "is_heading": 1,
                "text": "What is recorded as the DATE FIRST SEEN for screening cases?"
            },
            "type": "ListItem",
            "sequence_num": 300
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The DATE FIRST SEEN for the individual screening programmes are as follows:"
            },
            "type": "ListItem",
            "sequence_num": 301
        },
        {
            "data": {
                "is_heading": 1,
                "text": "FIRST SEEN ADJUSTMENT for screening"
            },
            "type": "ListItem",
            "sequence_num": 302
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Even though there is no screening first seen standard, a first seen adjustment can be applied using the same rules as first appointment for a 2ww referral. This adjustment would then be applied to the FDS and if applicable the 62-day Screening Referral to Treatment Standard."
            },
            "type": "ListItem",
            "sequence_num": 303
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.32,
                "text": "Faster Diagnosis Standard (FDS)"
            },
            "type": "ListItem",
            "sequence_num": 304
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.33,
                "text": "FDS summary:"
            },
            "type": "ListItem",
            "sequence_num": 305
        },
        {
            "type": "table",
            "sequence_num": 306,
            "data": {
                "num_rows": 2,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Standard"
                    },
                    {
                        "text": "Applies to"
                    },
                    {
                        "text": "Start"
                    },
                    {
                        "text": "Stop"
                    },
                    {
                        "text": "Target"
                    },
                    {
                        "text": "Operational Standard"
                    },
                    {
                        "text": "FDS"
                    },
                    {
                        "text": "Patients who have been referred by GMP/GDP/Optometrist for suspected cancer, breast symptomatic referral or urgent screening referral, must be informed of their diagnosis (either benign or malignant) within 28 days of referral"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Communication with patient informing them of their diagnosis, or the DTT date if treatment is given first"
                    },
                    {
                        "text": "28 days"
                    },
                    {
                        "text": "75%"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.34,
                "text": "Starting the clock and inclusion of FDS"
            },
            "type": "ListItem",
            "sequence_num": 307
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 28-day FDS inclusion and clock start dates are the same as detailed in section 5.5 of this policy."
            },
            "type": "ListItem",
            "sequence_num": 308
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.35,
                "text": "FDS time adjustments"
            },
            "type": "ListItem",
            "sequence_num": 309
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The only waiting time adjustment which can be recorded for the 28-day FDS are those applicable to the first seen date where a patient DNAs their first attendance. Details of the application of this adjustment are contained in section 5.5.6 and 5.5.10.2.C (screening specifics) of this policy."
            },
            "type": "ListItem",
            "sequence_num": 310
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.36,
                "text": "Ending the FDS pathway"
            },
            "type": "ListItem",
            "sequence_num": 311
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The 28-day FDS pathway ends only at the point of communication with the patient, whether that is to inform them of a diagnosis of cancer, a ruling out, or if they are going to have treatment before a clinical diagnosis of cancer can be made."
            },
            "type": "ListItem",
            "sequence_num": 312
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where all reasonable diagnostics to exclude cancer have been completed and the patient is discharged back to their GP, the point at which this is"
            },
            "type": "ListItem",
            "sequence_num": 313
        },
        {
            "data": {
                "is_heading": 0,
                "text": "communicated to the patient should be recorded as the end of the 28-day FDS pathway. In such scenarios this should be recorded as a ruling out of cancer."
            },
            "type": "ListItem",
            "sequence_num": 314
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where the 28-day FDS pathway is a shared pathway, only the provider communicating the diagnosis to the patient will be expected to record and submit the end of the pathway FDS data items. This provider should also feedback this information to other providers involved in the patient's pathway."
            },
            "type": "ListItem",
            "sequence_num": 315
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.37,
                "text": "Communicating the diagnosis to a patient"
            },
            "type": "ListItem",
            "sequence_num": 316
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All diagnoses of cancers should be made through direct face-to-face communication with the patient, unless otherwise explicitly agreed with the patient."
            },
            "type": "ListItem",
            "sequence_num": 317
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Reasonable forms of communication with patients to confirm cancer has been ruled out include:"
            },
            "type": "ListItem",
            "sequence_num": 318
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where direct communication is not possible due to the patient not having the mental capacity to understand a diagnosis either temporarily or permanently, communication to the patient's recognised carer or a parent/guardian should be recorded in the same way as if the patient was told directly."
            },
            "type": "ListItem",
            "sequence_num": 319
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Example where this could apply are:-"
            },
            "type": "ListItem",
            "sequence_num": 320
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This would not be appropriate where it is not possible to contact a patient."
            },
            "type": "ListItem",
            "sequence_num": 321
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Communication must be easy to understand, and support must be available to patients who would like further information. Sites should undertake audits of their communication practice to ensure that letters/emails are being received and understood by patients. An accurate record of all communication as confirmed by the patient must be maintained in the patient record."
            },
            "type": "ListItem",
            "sequence_num": 322
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In the case of direct communication of the diagnosis with the patient either face to face or via phone, Skype or similar the date of the conversation should be recorded as the CANCER FASTER DIAGNOSIS PATHWAY END DATE."
            },
            "type": "ListItem",
            "sequence_num": 323
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient has expressed a preference for telephone communication, calls to confirm test results should be booked in the same way as triage appointments or outpatient appointments. Where a patient does not respond to a call, every effort should be made to contact the patient and book a new call at a different time or another date. In such a scenario the pathway should continue until the communication is made."
            },
            "type": "ListItem",
            "sequence_num": 324
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where an e-mail is sent the CANCER FASTER DIAGNOSIS PATHWAY END DATE should be recorded as the email sent date."
            },
            "type": "ListItem",
            "sequence_num": 325
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a letter is sent the CANCER FASTER DIAGNOSIS PATHWAY END DATE should be recorded as the letter sent date."
            },
            "type": "ListItem",
            "sequence_num": 326
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where an arrangement is made for a healthcare professional in primary care for example the patient's GP to inform the patient of their diagnosis the date of this communication can only be recorded as the CANCER FASTER DIAGNOSIS PATHWAY END DATE where MSEFT has a clear record of this communication. In such cases ORGANSATION SITE IDENTIFIER (OF CANCER FASTER DIAGNOSIS PATHWAY END DATE) should be recorded as a MSEFT hospital site being responsible for communication of diagnosis."
            },
            "type": "ListItem",
            "sequence_num": 327
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.38,
                "text": "Patients having interval scan/test"
            },
            "type": "ListItem",
            "sequence_num": 328
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In a case where a patient is ordered an interval scan or test, the 28-day FDS clock will stop."
            },
            "type": "ListItem",
            "sequence_num": 329
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The CANCER FASTER DIAGNOSIS STANDARD PATHWAY END DATE should be recorded as the date the patient is told that this is the plan. The CANCER FASTER DIAGNOSIS STANDARD PATHWAY END REASON should be recorded as \u201804 \u2013 Interval Scanning'."
            },
            "type": "ListItem",
            "sequence_num": 330
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This should only be applied where:-"
            },
            "type": "ListItem",
            "sequence_num": 331
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Examples where this would not apply are:-"
            },
            "type": "ListItem",
            "sequence_num": 332
        },
        {
            "data": {
                "is_heading": 0,
                "text": "It is important that patients having interval scans are tracked and monitored to ensure the scan or test is completed when planned."
            },
            "type": "ListItem",
            "sequence_num": 333
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient is subsequently diagnosed with cancer following an interval scan, a new pathway should be recorded. It would be good practice at this stage, to upgrade the patient on to the 62-day upgrade standard."
            },
            "type": "ListItem",
            "sequence_num": 334
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.39,
                "text": "Diagnostic uncertainty"
            },
            "type": "ListItem",
            "sequence_num": 335
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient on the 28-day FDS pathway cannot be given a formal non- malignant diagnosis and is followed up due to diagnostic uncertainty the patient remains on the 28-day FDS tracking until either a cancer diagnosis is made or a non-malignant diagnosis is confirmed and this is communicated to the patient. The two exceptions to this is where an interval scanning is arranged as detailed in section 5.6.4.2 above and if a patient declines all diagnostics and thus excluded from the standard."
            },
            "type": "ListItem",
            "sequence_num": 336
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Diagnoses of a different type of cancer than initially referred"
            },
            "type": "ListItem",
            "sequence_num": 337
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For a patient where a specific cancer is ruled out, but is still considered high risk and requiring further urgent investigation, an inter-specialism referral should be considered the normal course of action. The 28-day FDS clock continues to run until suspicion of cancer has been reasonably ruled out."
            },
            "type": "ListItem",
            "sequence_num": 338
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient is referred for a suspected cancer and a different cancer is incidentally found that is unrelated to the referral, the 28-day FDS pathway will end when the patient is told their diagnosis or, where it comes first, the decision to treat the incidental cancer."
            },
            "type": "ListItem",
            "sequence_num": 339
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.41,
                "text": "Cancers of unknown primary"
            },
            "type": "ListItem",
            "sequence_num": 340
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 28-day FDS is to the point at which a patient is either told they have cancer or cancer is excluded. For the purposes of the 28-day FDS, if a patient is told they have cancer but the primary site is currently unknown then this would act as a clock stop and CANCER PRIMARY SITE (CANCER FASTER DIAGNOSIS PATHWAY) recorded as 15 - Metastatic disease of unknown primary."
            },
            "type": "ListItem",
            "sequence_num": 341
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.42,
                "text": "Diagnosis of Cancer prior to referral"
            },
            "type": "ListItem",
            "sequence_num": 342
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient is told they have cancer prior to referral, this communication should be confirmed when the patient is first seen and the CANCER FASTER DIAGNOSIS PATHWAY END DATE should be recorded as the FIRST SEEN DATE."
            },
            "type": "ListItem",
            "sequence_num": 343
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.43,
                "text": "Diagnosis of recurrence of previously treated cancer"
            },
            "type": "ListItem",
            "sequence_num": 344
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient has been previously diagnosed and treated for cancer and is referred via an Urgent Suspected Cancer, Breast Symptomatic or Urgent Screening referral then the 28-day FDS will apply."
            },
            "type": "ListItem",
            "sequence_num": 345
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where the patient is told that they have cancer, it may be unclear if the tumour is a new primary cancer or a secondary site from the previously diagnosed cancer. The 28-day FDS would still stop at this point with the CANCER FASTER DIAGNOSIS END REASON being recorded as 01- Diagnosis of Cancer and the CANCER PRIMARY SITE (CANCER FASTER DIAGNOSIS PATHWAY) recorded as the site of the tumour."
            },
            "type": "ListItem",
            "sequence_num": 346
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The relevant first definitive treatment standard would only apply if this tumour was then shown to be a new primary."
            },
            "type": "ListItem",
            "sequence_num": 347
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.44,
                "text": "Ending the faster diagnosis standard pathway before diagnosis"
            },
            "type": "ListItem",
            "sequence_num": 348
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In most cases, the pathway will end when the patient is informed that the possibility of cancer has been ruled out or that they have been diagnosed with cancer."
            },
            "type": "ListItem",
            "sequence_num": 349
        },
        {
            "data": {
                "is_heading": 0,
                "text": "However, there may be cases where a decision to treat is made before a diagnosis is made and communicated to the patient, for example, skin or ovarian cancers."
            },
            "type": "ListItem",
            "sequence_num": 350
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In such cases the CANCER TREATMENT PERIOD START DATE should be recorded as the decision to treat date. Then once the patient is told their diagnosis post treatment, the CANCER FASTER DIAGNOSIS PATHWAY END DATE should be recorded as the date of communication with the patient."
            },
            "type": "ListItem",
            "sequence_num": 351
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For reporting purposes the CANCER FASTER DIAGNOSIS END DATE will be used to derive the reporting month, with the CANCER TREATMENT PERIOD START DATE being used for the calculation where this is before this date."
            },
            "type": "ListItem",
            "sequence_num": 352
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The activity would be allocated to the provider communicating the diagnosis or ruling out of cancer even if the decision to treatment occurred at another trust. The CANCER FASTER DIAGNOSIS END DATE should still be recorded as the date of the diagnosis of cancer or ruling out of cancer is communicated to the patient."
            },
            "type": "ListItem",
            "sequence_num": 353
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.45,
                "text": "Histological diagnosis"
            },
            "type": "ListItem",
            "sequence_num": 354
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In some instances the clinical team will want to wait until they have the histology results before making a decision as to whether the patient has cancer. In these circumstances the faster diagnosis pathway would end after a histological diagnosis, at the point the outcome is communicated with the patient. This does not need to happen for all patients, as the clinical team can consider they have enough information to communicate a diagnosis or ruling out of cancer before having the histological result."
            },
            "type": "ListItem",
            "sequence_num": 355
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.46,
                "text": "Cancer outside of scope of treatment standards"
            },
            "type": "ListItem",
            "sequence_num": 356
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a cancer is diagnosed but is outside the scope of the treatment CWT standards, for the purposes of the 28-day FDS the CANCER FASTER DIAGNOSIS PATHWAY END REASON should be recorded as 02- Ruling out of Cancer."
            },
            "type": "ListItem",
            "sequence_num": 357
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Details of inclusions and exclusions for the treatment standards are included in tumour specific section of CWT v11 (section 6)."
            },
            "type": "ListItem",
            "sequence_num": 358
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.47,
                "text": "Exclusions from FDS"
            },
            "type": "ListItem",
            "sequence_num": 359
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient is excluded from the 28-day FDS the following fields should be completed:"
            },
            "type": "ListItem",
            "sequence_num": 360
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "CANCER FASTER DIAGNOSIS PATHWAY END REASON \u2013 Option  \u2013 Excluded from the cancer faster diagnosis standard."
            },
            "type": "ListItem",
            "sequence_num": 361
        },
        {
            "data": {
                "is_heading": 0,
                "text": "CANCER FASTER DIAGNOSIS PATHWAY END DATE \u2013 Recorded as the date the patient is discharged back to the GPs care, date of death or otherwise excluded depending on exclusion reason."
            },
            "type": "ListItem",
            "sequence_num": 362
        },
        {
            "data": {
                "is_heading": 0,
                "text": "CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON \u2013 With reason selected."
            },
            "type": "ListItem",
            "sequence_num": 363
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 28-day FDS will not apply to these patients, with the exception of when 01- Patient died before communication of diagnosis is selected as the CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON in which case the patient would be included if the date of death is more than 28 days after the clock start."
            },
            "type": "ListItem",
            "sequence_num": 364
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The below sets out the exclusion reasons and the scenarios where they can apply:"
            },
            "type": "ListItem",
            "sequence_num": 365
        },
        {
            "type": "table",
            "sequence_num": 366,
            "data": {
                "num_rows": 6,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Patient died before a communication of diagnosis (01)"
                    },
                    {
                        "text": "This is to be used where a patient dies before a communication of cancer diagnosis or exclusion of cancer. In such cases the CANCER FASTER DIAGNOSIS PATHWAY END DATE should be recorded as the date the patient died."
                    },
                    {
                        "text": "Patient declined all diagnostic appointments (02)"
                    },
                    {
                        "text": "This can only be used where a patient declines all diagnostics appointments and is therefore discharged back to the GPs care or exceptionally when agreed with the patient followed up routinely in secondary care. This cannot be used in the scenario where a patient declines or delays one or more diagnostics and the patient, is still followed up urgently in hospital, for example with alternative diagnostics, or the patient asks for time to consider if they would like a diagnostic."
                    },
                    {
                        "text": "Patient declined all appointments (03)"
                    },
                    {
                        "text": "This can only be used where a patient declines all appointments and is therefore discharged back to the GPs care. In this scenario this should be clearly communicated to the GP."
                    },
                    {
                        "text": "Patient opted for private diagnostics (Patient may come back for NHS funded treatment) (04)"
                    },
                    {
                        "text": "This can be applied where a patient has opted to have their diagnostics through private funding. This should not be applied if NHS diagnostics are sub- contracted to a private provider as the activity would still be NHS funded and a NHS provider would still be commissioned to provide the diagnostics."
                    },
                    {
                        "text": "Repeated Did Not Attends (DNAs)/Patient triggered cancellations (05)"
                    },
                    {
                        "text": "This can only be applied following multiple DNAs and patient cancellations where a clinical decision is made to discharge the patient back to the GPs care, as per reasonable offers section 5.5.8."
                    },
                    {
                        "text": "Patient ineligible for NHS funded care (06)"
                    },
                    {
                        "text": "This can be applied if a patient is found to be ineligible for NHS funded care, and as a result is discharged by MSEFT. This cannot be applied if a patient continues on the pathway under NHS care."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 31.0,
                "text": "Treatment (31 day) Standard Specifics Treatment  day standards summary"
            },
            "type": "ListItem",
            "sequence_num": 367
        },
        {
            "type": "table",
            "sequence_num": 368,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Standard"
                    },
                    {
                        "text": "Applies to"
                    },
                    {
                        "text": "Start"
                    },
                    {
                        "text": "Stop"
                    },
                    {
                        "text": "Target"
                    },
                    {
                        "text": "Operational Standard"
                    },
                    {
                        "text": "31 Day (First Treatment)"
                    },
                    {
                        "text": "All patients diagnosed with cancer have to be given their first treatment within 31 days of the date the patient agrees to have the treatment"
                    },
                    {
                        "text": "Decision to treat (when the patient agrees to have the treatment)"
                    },
                    {
                        "text": "Treatment date; or Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": "31 days"
                    },
                    {
                        "text": "96%"
                    },
                    {
                        "text": "31 Day (Subsequent Treatment)"
                    },
                    {
                        "text": "Patients having subsequent treatments also have to be treated within 31 days of the date the patient agrees to have the treatment"
                    },
                    {
                        "text": "Decision to treat (when the patient agrees to have the treatment)"
                    },
                    {
                        "text": "Treatment date; or Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": "31 days"
                    },
                    {
                        "text": "94% for surgery 94% for radiotherapy 98% for SACT"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.49,
                "text": "Coverage of the Treatment standards"
            },
            "type": "ListItem",
            "sequence_num": 369
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Treatment CWT service standards are applicable to patients cared for under the NHS in England with ICD codes C00-C97 (excluding basal cell carcinoma of Skin, WHO grade 1 or 2 brain cancers, and pTa bladder tumours) and D05 (carcinoma in situ \u2013 breast). This includes those patients:"
            },
            "type": "ListItem",
            "sequence_num": 370
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Being treated within a clinical trial;"
            },
            "type": "ListItem",
            "sequence_num": 371
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Whose cancer care is undertaken by a private provider on behalf of the NHS, i.e. directly commissioned by an English NHS commissioner"
            },
            "type": "ListItem",
            "sequence_num": 372
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Whose care is sub-contracted to another provider \u2013 including a private provider \u2013 (and hence paid for) by an English NHS provider, i.e. commissioned by an English NHS commissioner but subcontracted out by the commissioned provider;"
            },
            "type": "ListItem",
            "sequence_num": 373
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Diagnosed with a second new cancer;"
            },
            "type": "ListItem",
            "sequence_num": 374
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Without microscopic verification of the tumour (i.e. histology or cytology) if the patient has been told they have cancer and/or have received treatment for cancer; or"
            },
            "type": "ListItem",
            "sequence_num": 375
        },
        {
            "data": {
                "is_heading": 0,
                "text": "With any skin squamous cell carcinoma (SCC)."
            },
            "type": "ListItem",
            "sequence_num": 376
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 31day standard applies to:"
            },
            "type": "ListItem",
            "sequence_num": 377
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS patients with a newly diagnosed invasive cancer (localised or metastatic), regardless of the route of referral."
            },
            "type": "ListItem",
            "sequence_num": 378
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS patients with a recurrence of a previously diagnosed cancer, regardless of the route of referral."
            },
            "type": "ListItem",
            "sequence_num": 379
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients who choose initially to be seen privately but are then referred for first and/or subsequent treatments in the NHS."
            },
            "type": "ListItem",
            "sequence_num": 380
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Decision to treat (DTT)"
            },
            "type": "ListItem",
            "sequence_num": 381
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Decision to treat (DTT) date is the date the patient agrees a treatment plan, i.e. the date that a consultation between the patient and the clinician (face to face/telephone) took place and a Planned Cancer Treatment was agreed. This is recorded as the CANCER TREATMENT PERIOD START DATE."
            },
            "type": "ListItem",
            "sequence_num": 382
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The date the patient signs the consent form may, depending on administrative procedures locally, take place some days after the DTT. It is advised that the meeting at which the treatment plan is agreed is classed as the DTT, not the date the consent form is signed. If a patient is having a joint procedure (e.g. Breast mastectomy with immediate reconstruction) the DTT date would be the first consultation where the intent to do a joint treatment was agreed, regardless of which clinical team the agreement was with."
            },
            "type": "ListItem",
            "sequence_num": 383
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 31.0,
                "text": "The DTT date constitutes the clock start for the  day treatment standard."
            },
            "type": "ListItem",
            "sequence_num": 384
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the patient subsequently changes their mind about their treatment plan for example they have agreed surgery but decide they would instead prefer SACT then the DTT date can be amended to the new decision however the 62 day period would continue unchanged."
            },
            "type": "ListItem",
            "sequence_num": 385
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Commissioner applications for treatment funding cannot reset the 31-day standard clock."
            },
            "type": "ListItem",
            "sequence_num": 386
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient has seen a consultant in the private sector and the decision to treat is made there and they subsequently decide to have treatment at the Trust, the DTT date is the date that the trust accepts the referral even if it is with the same consultant."
            },
            "type": "ListItem",
            "sequence_num": 387
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.51,
                "text": "First definitive treatment (FDT)"
            },
            "type": "ListItem",
            "sequence_num": 388
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The FDT is normally the first intervention which is intended to remove, debulk or shrink the tumour."
            },
            "type": "ListItem",
            "sequence_num": 389
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where no definitive anti-cancer treatment is planned almost all patients will be offered a palliative intervention (e.g. stenting) or palliative care (e.g. pain relief), which should be recorded for these purposes."
            },
            "type": "ListItem",
            "sequence_num": 390
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a procedure is intended to be \u2018anti-cancer' but is unsuccessful, such as an open and close surgery where the tumour is not removed, then this is still classed as a FDT."
            },
            "type": "ListItem",
            "sequence_num": 391
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient is treated for one suspected cancer but found to have a different cancer to that which was suspected (i.e. the original diagnosis was incorrect) and the original treatment was not able to treat the newly identified cancer, then the original treatment is not classed as a FDT. Even though the treatment had an anti-cancer intention it is more important that the patient is continued to be monitored to ensure they are re-diagnosed and treated as quickly as possible."
            },
            "type": "ListItem",
            "sequence_num": 392
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A diagnostic procedure, undertaken as therapeutic in intent (i.e. the intention is to remove or debulk the tumour), will count as a FDT irrespective of whether the margins were clear."
            },
            "type": "ListItem",
            "sequence_num": 393
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A purely diagnostic procedure (including biopsy) does not count as a FDT unless the tumour is effectively removed by the procedure. If the intention was diagnostic and the excised tissue was found to be malignant the procedure could count as a FDT if the tumour has effectively been completely removed by the excision."
            },
            "type": "ListItem",
            "sequence_num": 394
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Of note, CWT v11 advice:"
            },
            "type": "ListItem",
            "sequence_num": 395
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Prostate \u2013 patients with low and low-to-intermediate prostate cancer should be recorded as \u2018Active Monitoring' when informed of diagnosis as it is recognised that this cohort of patients do not clinically require rapid treatment and will often benefit from time to consider treatment options. Refer to section 5.7.9."
            },
            "type": "ListItem",
            "sequence_num": 396
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Bladder \u2013 TURBT will now only be classed as a FDT if the entire tumour has been effectively removed by the procedure. Previous advice was that all TURBTs were recorded as a treatment irrespective of amount of tumour removed."
            },
            "type": "ListItem",
            "sequence_num": 397
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Metastatic Disease \u2013 treatment for metastases from a known primary can now be recorded as a FDT."
            },
            "type": "ListItem",
            "sequence_num": 398
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Refer to section 6 of the CWT v11 for what can or cannot be counted as a FDT, per tumour site."
            },
            "type": "ListItem",
            "sequence_num": 399
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.52,
                "text": "Incidental findings"
            },
            "type": "ListItem",
            "sequence_num": 400
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Some patients may be diagnosed with cancer during routine investigations where cancer has not been suspected or while being treated for another condition, i.e. incidental findings."
            },
            "type": "ListItem",
            "sequence_num": 401
        },
        {
            "data": {
                "is_heading": 0,
                "text": "These patients should be monitored under the 31-day decision to treat (DTT) to treatment standard. Where the patient is treated immediately at the point of diagnosis, the DTT (recorded as CANCER TREATMENT PERIOD START DATE) will be the same date as the date of the admission (e.g. when a patient is incidentally found to have a cancer during surgery for a suspected benign condition)."
            },
            "type": "ListItem",
            "sequence_num": 402
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient is referred as a two week wait for a suspected cancer and a different cancer is incidentally found that is unrelated to the referral, the Faster Diagnosis Pathway period would end with the communication of diagnosis, or (where it comes first) DTT, for the incidental cancer. Although the cancer diagnosis was incidental, it was found during investigations as part of the 2ww referral."
            },
            "type": "ListItem",
            "sequence_num": 403
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient is referred as a two week wait and a cancer is incidentally found that is unrelated to the referral, the 62-day period would end with the first definitive treatment (FDT) for the incidental cancer. Although the cancer diagnosis was incidental, it was found during investigations as part of the 2ww referral."
            },
            "type": "ListItem",
            "sequence_num": 404
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.53,
                "text": "Multiple diagnoses"
            },
            "type": "ListItem",
            "sequence_num": 405
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients diagnosed with two primary cancers as a result of one two week wait referral from primary care would be recorded using two PATIENT PATHWAY IDENTIFIERs."
            },
            "type": "ListItem",
            "sequence_num": 406
        },
        {
            "data": {
                "is_heading": 0,
                "text": "One would be generated at the point of referral and the other when the second primary is first suspected and the new (parallel) pathway starts."
            },
            "type": "ListItem",
            "sequence_num": 407
        },
        {
            "data": {
                "is_heading": 0,
                "text": "There would be only one 28-day FDS/62-day pathway linked to this referral, relating to the initial 2ww referral and diagnosis. The second cancer would be considered a 31-day pathway only, unless a consultant upgrade takes place, in which case the second primary would also be covered by the 62- day consultant upgrade pathway."
            },
            "type": "ListItem",
            "sequence_num": 408
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.54,
                "text": "Enabling treatments"
            },
            "type": "ListItem",
            "sequence_num": 409
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The enabling treatments that can be classed as FDTs (regardless of setting) are:"
            },
            "type": "ListItem",
            "sequence_num": 410
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Colostomy for bowel obstruction where this is necessary prior to definitive treatment unless this is necessary due to the length of wait for definitive treatment."
            },
            "type": "ListItem",
            "sequence_num": 411
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Stenting where this is necessary prior to definitive treatment unless this is necessary due to the length of wait for definitive treatment (e.g. oesophageal stent, uterine stenting for advanced cervical cancer, pancreatic or biliary stent to relieve jaundice and colonic stent to relieve an obstruction)."
            },
            "type": "ListItem",
            "sequence_num": 412
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Gastrojejunostomy."
            },
            "type": "ListItem",
            "sequence_num": 413
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Portal vein embolization prior to surgery for liver cancer (primary or secondary) to allow liver growth prior to surgery."
            },
            "type": "ListItem",
            "sequence_num": 414
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Dental extractions to enable radiotherapy."
            },
            "type": "ListItem",
            "sequence_num": 415
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Percutaneous gastrostomy line insertions."
            },
            "type": "ListItem",
            "sequence_num": 416
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Vaccinations prior to removal of spleen."
            },
            "type": "ListItem",
            "sequence_num": 417
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Trans-positioning of ovaries (for preserving fertility/side effects)."
            },
            "type": "ListItem",
            "sequence_num": 418
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Drugs which form part of SACTregimens which commence prior to SACT drugs [e.g. a clock stop can be applied a week earlier than the commencement of pemetrexed-containing protocols, when hydroxocobalamin (B12) injection is administered as a pre-medication]."
            },
            "type": "ListItem",
            "sequence_num": 419
        },
        {
            "data": {
                "is_heading": 1,
                "text": "The following are procedures which would not count as an enabling treatment based on previous advice:"
            },
            "type": "ListItem",
            "sequence_num": 420
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Iron tablets."
            },
            "type": "ListItem",
            "sequence_num": 421
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Monofer or ferinject iron infusion (though active monitoring guidance should be referenced)."
            },
            "type": "ListItem",
            "sequence_num": 422
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Peripherally inserted central catheter line insertions."
            },
            "type": "ListItem",
            "sequence_num": 423
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cystodiathermy."
            },
            "type": "ListItem",
            "sequence_num": 424
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Placement of rectal spacer prior to radiotherapy."
            },
            "type": "ListItem",
            "sequence_num": 425
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.55,
                "text": "SACT"
            },
            "type": "ListItem",
            "sequence_num": 426
        },
        {
            "data": {
                "is_heading": 0,
                "text": "SACT is used as the FDT under the following circumstances:"
            },
            "type": "ListItem",
            "sequence_num": 427
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Chemotherapy (including prior to planned surgery/radiotherapy)"
            },
            "type": "ListItem",
            "sequence_num": 428
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Biological therapy including treatments targeted against a specific molecular abnormality in the cancer cell (e.g. rituximab, trastuzumab, imatimib) and treatments which target the immune system (e.g. interferon, interleukin 2, BCG)"
            },
            "type": "ListItem",
            "sequence_num": 429
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Hormone treatments when given as the sole treatment modality or if the treatment plan specifies that a second treatment modality should only be given after a planned interval."
            },
            "type": "ListItem",
            "sequence_num": 430
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If SACT is to be self-administered, the TREATMENT START DATE (CANCER) should be recorded as the date of the outpatient appointment where the patient is given the prescription."
            },
            "type": "ListItem",
            "sequence_num": 431
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.56,
                "text": "Palliative care and active monitoring"
            },
            "type": "ListItem",
            "sequence_num": 432
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Specialist palliative care is delivered under the management of a team led by a consultant in palliative medicine."
            },
            "type": "ListItem",
            "sequence_num": 433
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Specialist Palliative Care (SPC) is provided when no active treatment is planned via:"
            },
            "type": "ListItem",
            "sequence_num": 434
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Refer to CWT v11 for exclusions/inclusion of SPC in non-NHS hospices."
            },
            "type": "ListItem",
            "sequence_num": 435
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Non-Specialist Palliative Care is any palliative care (excluding active monitoring) that is not given under the management of a consultant in palliative medicine."
            },
            "type": "ListItem",
            "sequence_num": 436
        },
        {
            "data": {
                "is_heading": 1,
                "text": "If a patient is transferred to a local voluntary hospice for palliative treatment and no active treatment is planned then the date of the referral to the hospice would count as the start date of the treatment. This would be recorded by the NHS organisation that made the decision to transfer the patient to the independent palliative care provider"
            },
            "type": "ListItem",
            "sequence_num": 437
        },
        {
            "data": {
                "is_heading": 0,
                "text": "\u2018Active Monitoring' is where a cancer diagnosis has been reached, but it is not appropriate to give any active anti-cancer treatment at that point in time but an active treatment is still intended/may be required at a future date. The FDS clock will stop on the date the diagnosis is communicated to the patient."
            },
            "type": "ListItem",
            "sequence_num": 438
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The decision to whether it is appropriate to give a treatment should only consider the diagnosed cancer and not patient thinking time or other medical conditions that the patient has."
            },
            "type": "ListItem",
            "sequence_num": 439
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient is therefore monitored until a point in time when it is appropriate to give an active treatment for the diagnosed cancer. A patient would have to agree that they are choosing to be actively monitored for a period of time rather than receiving active cancer treatment."
            },
            "type": "ListItem",
            "sequence_num": 440
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Active monitoring may be used for any tumour site if appropriate and it would start on the date of the consultation where this plan of care was agreed with the patient. The one exception to this is a patient who is diagnosed with low or low-intermediate prostate cancer who would be recorded as active monitoring at the point the diagnosis is communicated to the patient, even if the patient is considering their treatment options."
            },
            "type": "ListItem",
            "sequence_num": 441
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Whilst a patient is being actively monitored they may receive symptomatic support."
            },
            "type": "ListItem",
            "sequence_num": 442
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient has active anti-cancer treatment planned, but has other comorbidities, as a result of the cancer, which need to be addressed before the active cancer treatment can commence then active monitoring can be used. Examples include:"
            },
            "type": "ListItem",
            "sequence_num": 443
        },
        {
            "data": {
                "is_heading": 1,
                "text": "It is not acceptable to use active monitoring as a means to end a 62-day period if the initial choice of FDT is not available within the standard time due to capacity problem or patient choice."
            },
            "type": "ListItem",
            "sequence_num": 444
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.57,
                "text": "Radiotherapy (RT)"
            },
            "type": "ListItem",
            "sequence_num": 445
        },
        {
            "data": {
                "is_heading": 1,
                "text": "RT is used as a FDT When used to treat either the primary site or to treat metastatic disease of a known or unknown primary."
            },
            "type": "ListItem",
            "sequence_num": 446
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.58,
                "text": "Surgery"
            },
            "type": "ListItem",
            "sequence_num": 447
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Surgery is used as a FDT in the following circumstances:"
            },
            "type": "ListItem",
            "sequence_num": 448
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Complete excision of a tumour."
            },
            "type": "ListItem",
            "sequence_num": 449
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Partial excision/debulking of a tumour (but not a biopsy for diagnostic or staging purposes unless it effectively removes the tumour even if margins are not clear)"
            },
            "type": "ListItem",
            "sequence_num": 450
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Palliative surgical interventions where no active treatment is planned to follow (e.g. formation of a colostomy for a patient with an obstructing bowel cancer, insertion of an oesophageal stent or pleurodesis)."
            },
            "type": "ListItem",
            "sequence_num": 451
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Refer to section 6 of the CWT v11 for what surgery can or cannot be counted as a FDT, per tumour site."
            },
            "type": "ListItem",
            "sequence_num": 452
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.59,
                "text": "Combined treatments and treatment packages"
            },
            "type": "ListItem",
            "sequence_num": 453
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For the purposes of the cancer waits dataset combined treatments are treatments of different modalities combined in a way that they must be scheduled to take place together. These should be regarded as single treatment packages."
            },
            "type": "ListItem",
            "sequence_num": 454
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Examples of combined treatments include:"
            },
            "type": "ListItem",
            "sequence_num": 455
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Chemo-radiotherapy - where radiotherapy and chemotherapy are delivered within a strict schedule so that they interact to make both treatments more effective (e.g. weekly 5FU during radiotherapy for rectal cancer, radiotherapy given synchronously with cycle 4 of CMF for breast cancer)"
            },
            "type": "ListItem",
            "sequence_num": 456
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Pre-operative or intra-operative radiotherapy - where radiotherapy is given just before or during surgery to maximise the effect of both treatments."
            },
            "type": "ListItem",
            "sequence_num": 457
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The definition of combined treatments excludes adjuvant therapies where each treatment can be scheduled separately. (E.g. breast surgery followed by post-operative radiotherapy, chemotherapy for small cell lung cancer followed by consolidation radiotherapy)."
            },
            "type": "ListItem",
            "sequence_num": 458
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Treating metastatic disease"
            },
            "type": "ListItem",
            "sequence_num": 459
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient receives treatment for a metastatic site tumour rather than the primary tumour first, this can be recorded as a first definitive treatment."
            },
            "type": "ListItem",
            "sequence_num": 460
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.61,
                "text": "Subsequent treatments and earliest clinically appropriate date (ECAD)"
            },
            "type": "ListItem",
            "sequence_num": 461
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All subsequent treatments for primary and recurrent cancer need to have a 31-day period recorded."
            },
            "type": "ListItem",
            "sequence_num": 462
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A subsequent treatment could be:"
            },
            "type": "ListItem",
            "sequence_num": 463
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An individual patient may receive one or a combination of these interventions."
            },
            "type": "ListItem",
            "sequence_num": 464
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The 31-day subsequent treatment standards do not cover follow on treatments that are not directly related to shrinking or delaying growth/spread of the cancer (e.g. closure of stomas, reconstructive surgery following initial surgery, rehabilitative and psychological services etc.)."
            },
            "type": "ListItem",
            "sequence_num": 465
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Subsequent treatments act in a similar way to the first treatment recorded under the 31-day standard. However, subsequent treatments can either start with a Decision To Treat (DTT) date or the ECAD (both are recorded as CANCER TREATMENT PERIOD START DATE)."
            },
            "type": "ListItem",
            "sequence_num": 466
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The ECAD is the earliest date that it is clinically appropriate for the next activity that actively progresses a patient along the pathway for that treatment to take place. This should be a previously agreed and clinically appropriate period of delay before the next treatment can commence. The activity may not always be the start of the treatment itself but could be the next appointment which deals with the planning of that treatment. When determining an ECAD only patient issues should be considered, not local capacity constraints."
            },
            "type": "ListItem",
            "sequence_num": 467
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient must be fully informed and agree to the ECAD."
            },
            "type": "ListItem",
            "sequence_num": 468
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The member of the consultant team liaising with the patient about the treatment in question would set the ECAD."
            },
            "type": "ListItem",
            "sequence_num": 469
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The ECAD can be with or without the presence of the patient and set at a number of points:"
            },
            "type": "ListItem",
            "sequence_num": 470
        },
        {
            "data": {
                "is_heading": 0,
                "text": "At the clinical review with the patient following the preceding treatment. If it is not possible to make a decision at the review a further review could be arranged."
            },
            "type": "ListItem",
            "sequence_num": 471
        },
        {
            "data": {
                "is_heading": 0,
                "text": "At the start of the preceding treatment if the patient will not be reviewed between treatments."
            },
            "type": "ListItem",
            "sequence_num": 472
        },
        {
            "data": {
                "is_heading": 0,
                "text": "At the MDT meeting if it is possible to identify the likely ECADs between treatments in an agreed package."
            },
            "type": "ListItem",
            "sequence_num": 473
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Following receipt of test results and prior to discussing with the patient if this is an appropriate date."
            },
            "type": "ListItem",
            "sequence_num": 474
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient does not have to be physically present on the date the ECAD is set as it can be set based on an earlier consultation."
            },
            "type": "ListItem",
            "sequence_num": 475
        },
        {
            "type": "image",
            "sequence_num": 476,
            "data": {
                "url": "MSEPO-21191 Cancer access policy 1.0.006.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The ECAD can be reviewed and changed any time up to the ECAD."
            },
            "type": "ListItem",
            "sequence_num": 477
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.62,
                "text": "Managing recurrences"
            },
            "type": "ListItem",
            "sequence_num": 478
        },
        {
            "data": {
                "is_heading": 0,
                "text": "When a patient, who has previously had cancer has a recurrent cancer diagnosis confirmed, the patient would proceed onto a 31day subsequent treatment pathway."
            },
            "type": "ListItem",
            "sequence_num": 479
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The dataset includes a data item CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS. One option to complete this field is \u2018Diagnosis of a recurrent cancer'. Once this field is completed such patients would automatically be excluded from 62-day standard by the CWT system."
            },
            "type": "ListItem",
            "sequence_num": 480
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the cancer diagnosed following a 2ww referral was in the same location or was the same type of cancer as a previously diagnosed cancer but is classed by the clinician as a new primary, then this would be a new 62-day"
            },
            "type": "ListItem",
            "sequence_num": 481
        },
        {
            "data": {
                "is_heading": 1,
                "text": "pathway, not a recurrence. For example, if a patient has left breast cancer and then is referred via 2ww at a later date with right breast cancer, then which pathway the patient is recorded under is dependent on the clinical decision as to whether this is a new primary or not."
            },
            "type": "ListItem",
            "sequence_num": 482
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.63,
                "text": "Clinical trials"
            },
            "type": "ListItem",
            "sequence_num": 483
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient has agreed to enter a clinical trial approved by an appropriate Ethics Committee (with a REC reference number) then the trial protocol will determine which treatments are classed as first or subsequent treatments respectively and they will be assigned as such under cancer waits standards. For example:"
            },
            "type": "ListItem",
            "sequence_num": 484
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patients should be made aware if there is a possibility they may receive a placebo as part of their treatment within a clinical trial."
            },
            "type": "ListItem",
            "sequence_num": 485
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "The CANCER TREATMENT MODALITY for a placebo would be classed as Code  \u2018anti-cancer drug regimen (other)' for cancer waits reporting purposes assuming it is known which patient had received the placebo instead of another type of anti-cancer drug regimen. If it is a blind trial, and it is not possible to identify which patient received which type of drug, then the \u2018anti-cancer drug regimen (other)' category would be used for each drug arm."
            },
            "type": "ListItem",
            "sequence_num": 486
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For clinical trials where the protocol sets the time-scales for delivery of treatment the clock stop should be recorded as the date that consent is given by the patient to be entered into the trial."
            },
            "type": "ListItem",
            "sequence_num": 487
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For cases where a patient is entered into a clinical trial, and this has no impact on when a treatment cancer be delivered, for example a trial which relates to post-surgical care, the clock stop should be recorded in the same way as if a patient was not on a clinical trial."
            },
            "type": "ListItem",
            "sequence_num": 488
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where combinations of treatments make up a single trial the enrolment date should be recorded as the treatment date, and the CANCER TREATMENT MODALITY should be recorded as the one which the patient is due to receive first"
            },
            "type": "ListItem",
            "sequence_num": 489
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.64,
                "text": "Patient choice treatment adjustment"
            },
            "type": "ListItem",
            "sequence_num": 490
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An adjustment for treatment can be applied if a patient declines a \u2018reasonable' offer of admission for treatment (for both admitted and non- admitted pathways)."
            },
            "type": "ListItem",
            "sequence_num": 491
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For cancer patients under the 31-day or 62-day standard, the adjustment would be the time between the date of the declined appointment (the offered a TCI) to the point when the patient could make themselves available for an alternative appointment."
            },
            "type": "ListItem",
            "sequence_num": 492
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a patient has agreed to a reasonable offer which they subsequently cancel/DNA, no pause is allowed and the clock continues."
            },
            "type": "ListItem",
            "sequence_num": 493
        },
        {
            "data": {
                "is_heading": 0,
                "text": "As part of the re-booking process the patient should be offered alternative dates for treatment."
            },
            "type": "ListItem",
            "sequence_num": 494
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If at the re-booking stage the patient declines a reasonable offer of treatment then an adjustment can be made. The clock is paused from the date of the earliest reasonable offer given. The end of the pause will be the new date that the patient states they are available from."
            },
            "type": "ListItem",
            "sequence_num": 495
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient makes themselves unavailable for treatment for a set period of time, then this may mean that offering actual dates which meet the reasonableness criteria would be inappropriate (as the provider would be offering dates that they know the patient cannot attend). In these circumstances the clock can be paused from the date of the earliest reasonable appointment that the provider would have been able to offer that patient. The WAITING TIME ADJUSTMENT REASON (TREATMENT) field should be completed with code \u20188 Patient Pause'. The clock would restart when the patient makes themselves available again."
            },
            "type": "ListItem",
            "sequence_num": 496
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If the patient has been offered a choice of treatments and they opt for one where there is insufficient capacity to provide the treatment within the standard deadline then it would not be possible to use an adjustment."
            },
            "type": "ListItem",
            "sequence_num": 497
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If you offer a choice of treatments and the patient asks about another treatment that, for example, the patient has heard about and, on reflection, it is deemed an appropriate treatment option then an adjustment would be possible as the patient declined a reasonable offer of treatment initially. The adjustment would be from the treatment or admission date that would have been offered and the clock restarts when the patient makes themselves available for a further appointment."
            },
            "type": "ListItem",
            "sequence_num": 498
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If an earlier appointment for the required treatment becomes available then it is good practice to offer this to the patient. If the patient already has a reasonable offer that they have agreed to and so decline this earlier offer then no adjustment should be applied."
            },
            "type": "ListItem",
            "sequence_num": 499
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.65,
                "text": "Clinically urgent treatment of another condition treatment adjustment"
            },
            "type": "ListItem",
            "sequence_num": 500
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An adjustment can be applied if it is deemed clinically essential to treat another medical condition before treatment for cancer can be given, after a decision to treat the cancer has been made."
            },
            "type": "ListItem",
            "sequence_num": 501
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In such cases the adjustment would apply from the point at which it is confirmed that a patient needs treatment for the other medical condition, to the point at which after receiving treatment for this condition the patient is deemed clinically fit to commence their cancer treatment."
            },
            "type": "ListItem",
            "sequence_num": 502
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This would be recorded with the WAITING TIME ADJUSTMENT REASON (TREATMENT) being recorded as \u2018Clinically urgent treatment of another condition'"
            },
            "type": "ListItem",
            "sequence_num": 503
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient is ordered diagnostics, or referred to another specialist to exclude another medical condition, an adjustment cannot be applied for the period in which the patient is waiting to be seen for this assessment or diagnostics. An adjustment can only be taken from the point at which another condition is diagnosed, and the patient deemed clinically unfit for their cancer treatment, prior to the other condition being treated."
            },
            "type": "ListItem",
            "sequence_num": 504
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This adjustment cannot be applied for where a patient is advised to make lifestyle changes for example stop smoking, lose weight or commence a period of pre-habilitation prior to their cancer treatment. In these cases, the patient clock would continue. The 62-day and 31-day threshold is set to allow for patients in this scenario who will exceed the timescales."
            },
            "type": "ListItem",
            "sequence_num": 505
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.66,
                "text": "Egg harvesting treatment adjustment"
            },
            "type": "ListItem",
            "sequence_num": 506
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where a patient opts for egg harvesting prior to their cancer treatment, an adjustment can be applied from the point at which the decision is made until the patient's cycle allows eggs to be harvested."
            },
            "type": "ListItem",
            "sequence_num": 507
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An adjustment cannot be applied for the period of time taken for the patient to wait to be seen by the egg harvesting service, only from the point at which the patient is seen by the service and agrees to egg harvesting to the point where harvesting takes place."
            },
            "type": "ListItem",
            "sequence_num": 508
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This would be recorded under the WAITING TIME ADJUSTMENT (TREATMENT) with the WAITING TIME ADJUSTMENT REASON (TREATMENT) being recorded as \u2018Egg Harvesting'."
            },
            "type": "ListItem",
            "sequence_num": 509
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.67,
                "text": "Referral/upgrade to first treatment standards"
            },
            "type": "ListItem",
            "sequence_num": 510
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.68,
                "text": "Referral/upgrade to first treatment standard summary"
            },
            "type": "ListItem",
            "sequence_num": 511
        },
        {
            "type": "table",
            "sequence_num": 512,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Standard"
                    },
                    {
                        "text": "Applies to"
                    },
                    {
                        "text": "Start"
                    },
                    {
                        "text": "Stop"
                    },
                    {
                        "text": "Target"
                    },
                    {
                        "text": "Operational Standard"
                    },
                    {
                        "text": "62 Day First Treatments"
                    },
                    {
                        "text": "Patients who are referred in by their GP/ dentist/optometrist with a priority of target and are then diagnosed with cancer have to be treated within 62 days"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Treatment date; or Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": "62 days"
                    },
                    {
                        "text": "85%"
                    },
                    {
                        "text": "Screening Patients (Breast,"
                    },
                    {
                        "text": "Patients who are referred in by the National Screening"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Treatment date; or"
                    },
                    {
                        "text": "62 days"
                    },
                    {
                        "text": "90%"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 513,
            "data": {
                "num_rows": 3,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Bowel or Cervical)"
                    },
                    {
                        "text": "Programmes and are then diagnosed with cancer have to be treated within 62 days"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Consultant Upgrades"
                    },
                    {
                        "text": "Patients who are upgraded by a member of the clinical team and are then diagnosed with a cancer have to be treated within 62 days"
                    },
                    {
                        "text": "Date patient was upgraded (this must be before the MDT Care Plan was agreed)"
                    },
                    {
                        "text": "Treatment date; or Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": "62 days"
                    },
                    {
                        "text": "Above the national average (around 90%)"
                    },
                    {
                        "text": "31 Day Rare Cancers (Acute Leukaemia, Testicular and Children's Cancers)"
                    },
                    {
                        "text": "Patients who are referred in by their GP with suspicion of acute leukaemia, testicular cancer or children's cancer have to be treated within 31 days"
                    },
                    {
                        "text": "Receipt of referral"
                    },
                    {
                        "text": "Treatment date; or Admission date; or Prescription date; or Palliative care referral date etc."
                    },
                    {
                        "text": "31 days"
                    },
                    {
                        "text": "No operational standard, measured within the 62 day classic)"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.69,
                "text": "Clock start for 62-day 2ww urgent"
            },
            "type": "ListItem",
            "sequence_num": 514
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Clock start \u2013 refer to 2ww"
            },
            "type": "ListItem",
            "sequence_num": 515
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 62.0,
                "text": "Clock start for  day consultant upgrade"
            },
            "type": "ListItem",
            "sequence_num": 516
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If a consultant upgrades a patient for a first primary cancer the 62-day period starts at the CONSULTANT UPGRADE DATE. Only those upgrades that are diagnosed with cancer and go on to treatment need to be reported."
            },
            "type": "ListItem",
            "sequence_num": 517
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A consultant or an authorised member of the consultant team can upgrade a patient if cancer is suspected. The ultimate responsibility for upgrades rests with the consultant responsible for the care of the patient who will have delegated their authority by local agreement. The upgrades could come from any part of the health service, not just from consultants and teams that most commonly see cancer patients."
            },
            "type": "ListItem",
            "sequence_num": 518
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.71,
                "text": "Can there be an upgrade from any source of referral?"
            },
            "type": "ListItem",
            "sequence_num": 519
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Yes, with the exception of the following as they are already on a cancer pathway:"
            },
            "type": "ListItem",
            "sequence_num": 520
        },
        {
            "data": {
                "is_heading": 0,
                "text": "2ww referrals for suspected cancer."
            },
            "type": "ListItem",
            "sequence_num": 521
        },
        {
            "data": {
                "is_heading": 0,
                "text": "2ww referrals for breast symptoms (not suspicious of cancer)."
            },
            "type": "ListItem",
            "sequence_num": 522
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Urgent screening referrals."
            },
            "type": "ListItem",
            "sequence_num": 523
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.72,
                "text": "Ending the 31/62 day pathways (clock stops)"
            },
            "type": "ListItem",
            "sequence_num": 524
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 31.0,
                "text": "The  day and 62-day standard stops with their first FDT. Refer to section 5.7.4."
            },
            "type": "ListItem",
            "sequence_num": 525
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.73,
                "text": "Referrals rare cancers (acute leukaemia, testicular cancer and children's cancer)"
            },
            "type": "ListItem",
            "sequence_num": 526
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 31.0,
                "text": "Urgent GP (GMP, GDP or Optometrist) referrals for suspected rare cancers should result in a 31-day period (rather than a 62-day period) from receipt of referral if a patient is diagnosed with one of these three types of cancer. If a patient is not urgently referred but a consultant suspects one of these cancers they can upgrade. The upgrade would, however, be on to the 62- day period although we would recommend that you agree a local policy to treat such patients within  days if possible. Irrespective of your local policy you will be performance managed against the 62-day pathway, not the 31-day pathway, for patients upgraded by a consultant when one of these three cancers is suspected."
            },
            "type": "ListItem",
            "sequence_num": 527
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.74,
                "text": "Adjustments"
            },
            "type": "ListItem",
            "sequence_num": 528
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The same adjustments apply to the 62-day standards, as are applied to the first seen and treatment phases of the pathway, and these are taken off the total waiting time. Details of these adjustments can be found here:-"
            },
            "type": "ListItem",
            "sequence_num": 529
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The first seen adjustment would only be subtracted from the 62-day consultant upgrade standard if the CONSULTANT UPGRADE DATE was before the first seen date."
            },
            "type": "ListItem",
            "sequence_num": 530
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.75,
                "text": "Cancer access rules (reasonable offers)"
            },
            "type": "ListItem",
            "sequence_num": 531
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Using the principles set out in NHS Improvement's Elective Care Model Access Policy, The Trust defines a \u2018reasonable' offer of a cancer appointment as:"
            },
            "type": "ListItem",
            "sequence_num": 532
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A patient is offered two dates in the future each with a three-week notice. If a patient declines two reasonable offers, they should be discharged back to the GP, provided this decision is endorsed by the patient's clinician who is responsible for their care."
            },
            "type": "ListItem",
            "sequence_num": 533
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Part of being reasonable means that the patient has been consulted and listened to, considering what the patient would find reasonable."
            },
            "type": "ListItem",
            "sequence_num": 534
        },
        {
            "data": {
                "is_heading": 0,
                "text": "In cases of contention, such as treatments offered on the same day, the commissioner should decide whether the offered appointment was reasonable."
            },
            "type": "ListItem",
            "sequence_num": 535
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The following scenarios are guides for services to assess when it would be most appropriate and suitable to discharge a patient back to primary care. However decision to discharge sits with the patient's clinician."
            },
            "type": "ListItem",
            "sequence_num": 536
        },
        {
            "type": "table",
            "sequence_num": 537,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Scenario*"
                    },
                    {
                        "text": "Resulting Action"
                    },
                    {
                        "text": "Patient declines offered outpatient/diagnostic appointment"
                    },
                    {
                        "text": "Offer telephone/video appointment where possible. Allow one cancellation/rebook (with 3 weeks' notice), if patient still declines then discharge to GP. If the patient accepts an offer with less than 3 weeks' notice, the offer will automatically become reasonable."
                    },
                    {
                        "text": "Patient declines to self-isolate as per current self-isolation guidance prior to a TCI date"
                    },
                    {
                        "text": "Record as declining offered date. Offer two reasonable offers (with 3 weeks' notice) \u2013 if patient declines 2 dates, discharge to GP. If the patient accepts an offer with less than 3 weeks' notice, the offer will automatically become reasonable."
                    },
                    {
                        "text": "Patient declines TCI date e.g. due to COVID concerns"
                    },
                    {
                        "text": "Record as declining offered date. Offer two reasonable offers (with 3 weeks' notice) \u2013 if patient declines 2 dates, discharge to GP. If the patient accepts an offer with less than 3 weeks' notice, the offer will automatically become reasonable."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "* does not include vulnerable adults or children."
            },
            "type": "ListItem",
            "sequence_num": 538
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.76,
                "text": "Inter provider transfers"
            },
            "type": "ListItem",
            "sequence_num": 539
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An inter-provider transfer (IPT) occurs when a patient follows a pathway of care that involves a referral between providers."
            },
            "type": "ListItem",
            "sequence_num": 540
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An inter-Provider Transfer (i.e. where the patient's pathway transfers from one provider to another for any reason) will not be recognised as a referral without receipt of the Clinical dataset and Cancer Waiting Times Datasets."
            },
            "type": "ListItem",
            "sequence_num": 541
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The inter-provider Transfer ensures the timely transfer of clinical and administrative information between providers when an IPT occurs."
            },
            "type": "ListItem",
            "sequence_num": 542
        },
        {
            "data": {
                "is_heading": 0,
                "text": "An inter-provider Transfer ensures patients receive appropriate assessment, diagnosis and treatment within the specified target times it is essential for referral information is sent to the provider within 24 hours of the decision to transfer."
            },
            "type": "ListItem",
            "sequence_num": 543
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient journey must be appropriately monitored, with key events communicated between all providers involved in the patient pathway"
            },
            "type": "ListItem",
            "sequence_num": 544
        },
        {
            "data": {
                "is_heading": 0,
                "text": "There should be no delays in the transfer of patients and problems in the process must be escalated appropriately and in a timely manner to the relevant staff so that remedial action can be taken."
            },
            "type": "ListItem",
            "sequence_num": 545
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 62.0,
                "text": "If a patients cannot be treated within the agreed  day performance standard the breach will be appropriately allocated between providers."
            },
            "type": "ListItem",
            "sequence_num": 546
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Refer to section 5.7 of the CWT v11 for detailed information on breach allocation."
            },
            "type": "ListItem",
            "sequence_num": 547
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.77,
                "text": "Auditing"
            },
            "type": "ListItem",
            "sequence_num": 548
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All patients who breach the treatment targets 31 and 62 days within cancer pathway will have a breach analysis undertaken by the MDT Co-ordinators in conjunction with Service Manager and the MDT clinical lead. These will be presented at monthly divisional governance meetings."
            },
            "type": "ListItem",
            "sequence_num": 549
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer Waiting List/MDT Managers will review cancer tracking and ensure all details are clear and entered on to Somerset Cancer Register; this will be the basis for any breach reporting."
            },
            "type": "ListItem",
            "sequence_num": 550
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Validation of all breach pathways will occur via the cancer support manager who will provide an unbiased view of the analysis using the information on Somerset Cancer Register."
            },
            "type": "ListItem",
            "sequence_num": 551
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ad-hoc challenge of pathway recoding will occur via the Cancer Manager and will take place as part of the Cancer PTL reviews using the information on the cancer PTL."
            },
            "type": "ListItem",
            "sequence_num": 552
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.78,
                "text": "Resource management"
            },
            "type": "ListItem",
            "sequence_num": 553
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The capacity and effectiveness of the MDT team will be reviewed yearly via the Cancer Manager and will be reported to the CSMB regarding outcomes."
            },
            "type": "ListItem",
            "sequence_num": 554
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This will ensure the team is adequately resourced and supported by the cancer team and the divisional operational and clinical leads for each tumour site for the tasked required of them including review of the tumour sites covered and MDT allocation's, and vacancies and plans to resolve this."
            },
            "type": "ListItem",
            "sequence_num": 555
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Service Managers are responsible for ensuring demand and capacity modelling is completed and updated at least yearly or when a service change occurs to ensure adequate capacity is in place to deliver the service."
            },
            "type": "ListItem",
            "sequence_num": 556
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.79,
                "text": "Performance overview and breach reporting"
            },
            "type": "ListItem",
            "sequence_num": 557
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Performance of all cancer standards are monitored by the divisional operation team and centrally by the corporate performance team."
            },
            "type": "ListItem",
            "sequence_num": 558
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A cancer PTL is available and updated at least 3 times a day for operational management of cancer pathways; this is used by the MDT Administration team and operational teams to track patients on a cancer patient to diagnosis and treatment."
            },
            "type": "ListItem",
            "sequence_num": 559
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All information relating to cancer treatments is logged by the MDT team on SCR to allow full tracking and validation of pathways."
            },
            "type": "ListItem",
            "sequence_num": 560
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Clinical Harm Reviews including timeline collection, incident reporting, and harm review harm allocation are to be conducted as per the current version of the MSEFT Cancer Harm Reviews SOP."
            },
            "type": "ListItem",
            "sequence_num": 561
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "Cancer PTL meetings"
            },
            "type": "ListItem",
            "sequence_num": 562
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer PTL meetings will occur weekly for each tumour site specialty"
            },
            "type": "ListItem",
            "sequence_num": 563
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Each specialty will be required to understand delays for each patient pathway and be able to provide the next steps including a plan to show how the patient will be treated before their breach date."
            },
            "type": "ListItem",
            "sequence_num": 564
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The specialties will also be expected to highlight upcoming capacity/clinical workforce constraints or delays within the service and what remedial action has been taken to counteract this."
            },
            "type": "ListItem",
            "sequence_num": 565
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "Once completed, actions will be sent out via the Cancer Performance Team with specialties expected to return answers within  hours."
            },
            "type": "ListItem",
            "sequence_num": 566
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Refer to the MSEPO-21192 Cancer escalation policy for more information."
            },
            "type": "ListItem",
            "sequence_num": 567
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.81,
                "text": "Training requirements"
            },
            "type": "ListItem",
            "sequence_num": 568
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All non/clinical staff will have Trust induction and PAS training. All non/clinical staff involved in cancer pathways will have specific local training in relation to the implementation of this policy and Somerset Cancer Register training provided by Cancer Services, supported by the Cancer Waiting list/MDT Managers. Additional or remedial training will be provided as required."
            },
            "type": "ListItem",
            "sequence_num": 569
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Monitoring and audit"
            },
            "type": "ListItem",
            "sequence_num": 570
        },
        {
            "type": "table",
            "sequence_num": 571,
            "data": {
                "num_rows": 6,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Aspect of compliance or effectiveness being monitored"
                    },
                    {
                        "text": "Monitoring Method"
                    },
                    {
                        "text": "Individual department responsible for the monitoring"
                    },
                    {
                        "text": "Frequency of the monitoring activity"
                    },
                    {
                        "text": "Group / Committee / forum which will receive the findings/monitoring report"
                    },
                    {
                        "text": "Committee / individual responsible for ensuring the actions are completed"
                    },
                    {
                        "text": "National / statutory requirements on access to services are being met."
                    },
                    {
                        "text": "Audit"
                    },
                    {
                        "text": "Clinical Directorates"
                    },
                    {
                        "text": "6 Monthly"
                    },
                    {
                        "text": "Clinical Assurance Committee"
                    },
                    {
                        "text": "Clinical Assurance Committee"
                    },
                    {
                        "text": "Cancer waiting times"
                    },
                    {
                        "text": "Daily pathway validation and production of monthly performance reports"
                    },
                    {
                        "text": "Cancer manager"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "Corporate cancer team"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Data Accuracy"
                    },
                    {
                        "text": "Sample of patients from each tumour group"
                    },
                    {
                        "text": "Cancer Data Quality Officer or equivalent"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "Corporate cancer team"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Inter Provider Transfer dates"
                    },
                    {
                        "text": "Tertiary referral dates validated with referring Trust"
                    },
                    {
                        "text": "Cancer information manager/ Cancer manager"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "Corporate cancer team"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Breach Validation"
                    },
                    {
                        "text": "Review of root cause analysis"
                    },
                    {
                        "text": "Directorate/ Divisional Management team"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "Corporate cancer team"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This policy will be formally approved by the Senior Management Team and agreed with commissioning partners. Alterations and amendments to this policy will be approved and ratified by these bodies."
            },
            "type": "ListItem",
            "sequence_num": 572
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Issues around interruption and application of this policy will be initially resolved by Head of Performance where any matter cannot be resolved at this level it will be escalated to the Cancer Service Board Group and Chief Operating Officer for resolution."
            },
            "type": "ListItem",
            "sequence_num": 573
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Compliance with this policy will be monitored as outlined in the Monitoring Compliance and Effectiveness section."
            },
            "type": "ListItem",
            "sequence_num": 574
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Compliance with this policy will be monitored as set out below."
            },
            "type": "ListItem",
            "sequence_num": 575
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Weekly validation checks as part of Cancer PTL review."
            },
            "type": "ListItem",
            "sequence_num": 576
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Monthly validation checks -All data fields are completed and submitted as required Totals are correct \u2013 e.g. that the total is a sum over all treatment functions large changes in volumes compared to previous months will be investigated."
            },
            "type": "ListItem",
            "sequence_num": 577
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Quarterly validation checks."
            },
            "type": "ListItem",
            "sequence_num": 578
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Approval and implementation"
            },
            "type": "ListItem",
            "sequence_num": 579
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This policy must be approved by MSEFT's commissioners prior to implementation."
            },
            "type": "ListItem",
            "sequence_num": 580
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Corporate services will ensure that the Policy is available on the intranet and the Trust website together with supporting procedure notes and that staff are notified."
            },
            "type": "ListItem",
            "sequence_num": 581
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Cancer Manager is responsible for ensuring the policy is disseminated to all divisions and cascaded."
            },
            "type": "ListItem",
            "sequence_num": 582
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Preliminary equality analysis"
            },
            "type": "ListItem",
            "sequence_num": 583
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            },
            "type": "ListItem",
            "sequence_num": 584
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "(Refer to appendix 1)"
            },
            "type": "ListItem",
            "sequence_num": 585
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 586
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 11.0,
                "text": "Cancer Waiting Times Version"
            },
            "type": "ListItem",
            "sequence_num": 587
        },
        {
            "data": {
                "is_heading": 0,
                "text": "MSE Patient Access Policy (MSEPO-20229)"
            },
            "type": "ListItem",
            "sequence_num": 588
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Going Further on Cancer Waits"
            },
            "type": "ListItem",
            "sequence_num": 589
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Achieving World Class Cancer Outcomes - A strategy for England 2015 -2020 Inter Provider Transfer Policy \u2013 East of England Strategic Clinical Network V.3"
            },
            "type": "ListItem",
            "sequence_num": 590
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Streamlining Multi-Disciplinary Team Meetings \u2013 Guidance for Cancer Alliances \u2013 Jan 2020"
            },
            "type": "ListItem",
            "sequence_num": 591
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer access policy / MSEPO-21191 / 1.0"
            },
            "type": "ListItem",
            "sequence_num": 592
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 56.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 593
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer access policy / MSEPO-21191 / 1.0"
            },
            "type": "ListItem",
            "sequence_num": 594
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix1: Preliminary equality analysis"
            },
            "type": "ListItem",
            "sequence_num": 595
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Cancer access policy / MSEPO-21191 (Please tick all that apply)"
            },
            "type": "ListItem",
            "sequence_num": 596
        },
        {
            "type": "table",
            "sequence_num": 597,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2610 A change to an existing document"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2612 A new document"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 598,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Aligning existing site-based information to become a new MSE policy"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Standardising the information across MSE"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "All nursing staff and managers"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 599,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Maureen Ross"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "General Manager \u2013 Cancer Access"
                    },
                    {
                        "text": "08 October 2021"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 55.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 600
        }
    ]
}